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Abstract: The growing availability of biomarker panels for molecular diagnostics is leading to
an increasing need for fast and sensitive biosensing technologies that are applicable to point-of-care
testing. In that regard, homogeneous measurement principles are especially relevant as they usually
do not require extensive sample preparation procedures, thus reducing the total analysis time
and maximizing ease-of-use. In this review, we focus on homogeneous biosensors for the in vitro
detection of biomarkers. Within this broad range of biosensors, we concentrate on methods that apply
magnetic particle labels. The advantage of such methods lies in the added possibility to manipulate
the particle labels by applied magnetic fields, which can be exploited, for example, to decrease
incubation times or to enhance the signal-to-noise-ratio of the measurement signal by applying
frequency-selective detection. In our review, we discriminate the corresponding methods based on
the nature of the acquired measurement signal, which can either be based on magnetic or optical
detection. The underlying measurement principles of the different techniques are discussed, and
biosensing examples for all techniques are reported, thereby demonstrating the broad applicability of
homogeneous in vitro biosensing based on magnetic particle label actuation.
Keywords: biosensor; magnetic nanoparticle; homogeneous assay; magnetorelaxation; AC susceptibility;
NMR; magnetic relaxation switch; asynchronous magnetorotation; magneto-optics; nanorod
1. Introduction
In the recent years, the growing availability and technical maturity of high-throughput
technologies for molecular sample analysis has led to an ever increasing number of biomarkers
reported in the literature [1,2]. Applications of these biomarkers include, for example, the diagnoses of
Alzheimer’s disease [3,4], chronic kidney disease [5], different types of cancer [6–10], diabetes [11,12],
liver diseases [13–15], tuberculosis [16–18], atherosclerotic vascular disease [19], cardiovascular
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diseases [20,21] or sepsis [22,23]. While the translation of the discovered biomarkers into clinical
practice still lags behind [24,25], some biomarkers are already successfully applied, for example the
S100B protein for improving patient stratification in cases of traumatic brain injury [26]. With the
increasing focus on clinical links and quality control of current biomarker studies [27], it can be
expected that the number of clinically relevant biomarker panels will substantially rise in the near
future, thus creating an ever stronger need for biosensing technologies that allow fast and sensitive
quantification of the respective biomarkers.
In order to classify the numerous biosensing technologies reported in the literature, we first
discriminate between measurement principles that can be applied in vivo from those measuring in vitro.
The present review focuses on methods that are employed in vitro. Another basic distinction can be
drawn between biosensors that make use of heterogeneous measurement principles and those that
measure signals generated within the entire homogeneous sample solution phase.
Heterogeneous biosensors rely on diffusion of the analyte molecules within the sample solution
volume towards the sensor surface for signal generation. A well-established state of the art
example of heterogeneous immunoassays is the enzyme-linked immunosorbent assay (ELISA).
While heterogeneous assay principles generally display high sensitivity and wide dynamic range,
labor intensive sample preparation steps that usually comprise multiple washing and incubation steps
are disadvantages that limit their applicability [28]. This especially accounts for point-of-care (PoC)
testing settings which necessitate sensor principles that can be applied outside clinical laboratories,
e.g., at the patient’s home for bedside monitoring or at the doctor’s office. Therefore, PoC testing
requires robust, rapid and automated sensor systems [29].
Homogeneous immunoassay principles rely on signal generation within the whole sample
volume [30]. Usually, the signal generating probes are mixed with the sample solution, and
measurements are carried out on this complex mixture. Such simple “mix and measure” techniques
offer great advantages for PoC testing applications since sample preparation requirements are
drastically reduced. Furthermore, the three dimensional diffusion of both, analyte molecules and
capture probes, leads to reduced total assay times compared to heterogeneous assay principles, where
the analyte molecules have to diffuse to a two dimensional capture surface before being detected [31,32].
In this paper, we review homogeneous measurement principles only.
Homogeneous measurement methods can be further subdivided into measurement methods
that make use of particles and particle-free approaches. Current state of the art examples of the
latter include fluorescence polarization [33,34], fluorescence correlation spectroscopy [35,36], Förster
resonance energy transfer (FRET) [37,38], molecular beacon-based sensor principles [39,40], or
thermophoresis [41–44]. Here, the fluorescence polarization measurement technique can also be
employed by making use of particles [45]. Sensing techniques that can be conducted homogeneously
and are based on particle labels include surface-enhanced Raman spectroscopy [46,47], particle
agglutination-based assays [48–51], and sensor principles based on magnetic particles. In this review,
we focus on homogeneous biosensors that make use of magnetic particle labels.
Generally, magnetic particles are already widely employed in biology and medicine [52–57].
For instance, magnetic resonance imaging (MRI) can be improved by applying magnetic nanoparticles
(NPs) as contrast agents, and the NPs can further be functionalized to specifically target the tissue
of interest [58,59]. MRI contrast agents affect the imaging signal that is generated within the tissue
surrounding the nanoparticle [58,59]. An alternative imaging modality is magnetic particle imaging
(MPI), where the measurement signal directly stems directly from the magnetization of the NP
labels. MPI offers the advantage of high contrast at short measurement times [60]. Besides medical
imaging, magnetic NPs are also used for therapeutic applications, e.g., for magnetic hyperthermia
treatment [61,62]. Here, the NPs are continuously re-magnetized in an external alternating magnetic
field, and the resulting energy dissipation leads to a local temperature rise in the tissue surrounding
the NPs. Thus, by targeting the NPs to cancer tissue, it is possible to specifically cause necrosis of
cancer cells [61,62]. Localization of magnetic NPs to a defined tissue volume is also key to magnetic
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drug delivery, which makes use of external magnetic gradient fields to generate forces that concentrate
drug loaded magnetic NPs to the targeted destination for drug release [63,64]. Once the magnetic
particles are fixed to specific cell types, these can be tracked in vivo or separated ex vivo on a chip for
further analysis [65,66]. Additionally, magnetic NPs are also applied for electrochemical, optical or
piezoelectric sensor principles [67]. The detection of biomarkers in vitro by magnetic particle labels
is in the central focus of the current review. A key advantage of magnetic particle labels is given by
the possibility to manipulate and actuate the particles by applying tailored magnetic fields, which can
be employed to accelerate incubation processes or enable frequency-selective analysis for improving
the signal-to-noise-ratio of the measurement signal. Biosensing principles which employ magnetic
particles for concentration, separation or washing steps only are excluded from this review as well as
chip-based measurement approaches involving microfluidics. Here, we refer to the existing review
literature [68–73].
A wide range of different methods to synthesize magnetic particles is reported in the
literature [52,74–81]. The most common techniques are hydrothermal synthesis, sol-gel-based
fabrication, microemulsion-based methods, high temperature decomposition of organometallic
precursors, electrochemical synthesis routes, co-precipitation, and strategies based on physical
condensation. Magnetic particles for biochemical applications require specific surface modifications to
ensure applicability in solutions of physiological conditions (salt concentration and pH value) as well
as to enable surface functionalization for specific recognition of target molecules [52,76,79,81–89].
In summary, the current review focuses on in vitro homogeneous biosensing approaches that
make use of magnetic particle labels and magnetic actuation. To that end, we first review methods
that detect the particle labels magnetically (Section 2), and later move on to optical detection methods
(Section 3).
2. Magnetic Detection Methods
In this section, we review in vitro homogenous biosensing principles that apply magnetic particle
labels and make use of magnetic detection methods. We distinguish between techniques that detect
the presence of magnetic particles by permeability measurements (see Section 2.1), methods that rely
on measuring changes of the hydrodynamic particle volume (see Section 2.2) and approaches that are
based on sensing the environment surrounding the particle labels by T2 relaxation nuclear magnetic
resonance (see Section 2.3).
Measurement approaches relying on surface binding of magnetic particle labels are not taken
into account here. Examples for such methods include Hall sensors [90–92], magnetoresistance based
techniques [93–98], or on-chip detection of magnetic flux density changes upon magnetic particle
binding [99,100]. In addition, methods relying on magnetic separation of particle labels in a microfluidic
channel [101] are also out of scope.
2.1. Magnetic Permeability Measurements
Magnetic permeability sensing is based on measuring the concentration of magnetic particles
in a sample. Fundamental to this approach is the substantially higher value of the relative magnetic
permeability of ferromagnetic materials compared to other substances, which allows to quantify the
number of magnetic particle labels within a given sample volume [102]. The method has initially been
introduced for bio-assay measurements by Kriz et al., who demonstrated an experimental setup for
measuring changes of the sample’s magnetic permeability in the presence of magnetic particles [102].
The technical realization is based on inserting the sample into a coil and measuring the inductance L,






with the relative magnetic permeability of the material inside the coil µr, the vacuum permeability
µ0, the cross section area A, the length of the applied coil l, and its number of windings N [102].
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The inductance is determined by applying the coil in a Maxwell bridge with two variable resistances
and by balancing the bridge at a driving AC current [102]. The setup can be employed for homogeneous
bio-assay measurements by introducing magnetic NP labels which bind to carrier microparticles via
analyte molecules (see sketch in Figure 1) [103–107]. While free magnetic NPs remain dispersed, the
microparticles sediment and, therefore, enrich the concentration of magnetic NPs at the bottom of the
sample vial in the presence of analyte molecules. The method can also be carried out as heterogeneous
assay by implementing further washing steps.
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Figure 1. Schematic measurement principle of the magnetic permeability sensing method:  
(a) Magnetic nanoparticles (NPs) and carrier microparticles with recognition molecules on the particle 
surfaces bind via analyte molecules. (b) The microparticles sediment, resulting in an analyte-
concentration dependent magnetic NP concentration at the bottom of the sample vial, which is placed 
in the center of the detection coil for determining its magnetic permeability. 
In their initial report, Kriz et al. demonstrated detection of glucose by magnetic permeability 
sensing [102]. Later, making use of a further developed measurement method, the authors showed 
the detection of concanavalin A (ConA) protein by unspecific binding processes to the particle 
surfaces [107]. Another demonstrated application concerns a one-step assay for measuring C-reactive 
protein (CRP) in both human and canine samples for point-of-care applications [104,105]. Measurements 
of whole blood samples from 50 patients have been compared to results obtained by different 
reference methods (a turbidimetric immunoassay and two commercially available PoC instruments), 
and good correlation to the magnetic permeability measurement method has been reported [105]. 
The measurement method is well-suited for PoC testing due to its one-step assay procedure and fast 
analysis time of only about 5.5 min [105]. Additionally, homogenous measurements of CRP from 
whole blood canine samples have been carried out in comparison to ELISA reference data [103]. 
Heterogeneous assay magnetic permeability measurements have been performed by detecting 
unbound magnetic NPs after a filtration step and correlating their concentration to the concentration 
of present CRP [106]. This assay has been integrated into a portable instrument that can be applied 
for PoC sensing [106]. Quantitative magnetic permeability measurements have been reported with a 
limit of detection (LoD) of 8 mg/L CRP, while reference ELISA reached a LoD of 3 mg/L [106]. 
Correlation analysis of the measured CRP biomarker concentrations in 47 canine serum samples to a 
commercial ELISA kit resulted in an excellent coefficient of determination of 98%, and the average 
values of about 6% for the intra- and inter-assay imprecision are also comparable to commercial 
ELISA kits [106]. 
Homogeneous analysis of albumin in urine samples of 149 individuals by magnetic permeability 
measurements has been reported by Lu et al. [108]. Albumin in urine serves as a protein biomarker 
for diabetes and hypertension patients who have a higher risk for developing a nephropathy [108]. 
Comparisons with the results of a turbidimetric immunoassay that serves as the hospital’s reference 
method show a good correlation with the magnetic permeability measurement results [108]. 
Finally, a proof of principle for the detection of DNA has been reported by Abrahamsson et al. 
by applying the magnetic permeability measurement method [109]. 
Figure 1. Schematic measurement principle of the magnetic permeability sensing method: (a) Magnetic
nanoparticles (NPs) and carrier mi roparticles with recognition olecules on the particle surfaces
bind via analyte molecul s; (b) The micr par icles sediment, resulting in an analyte-con ntration
dependent magnetic NP concentration at the bottom of the sample vial, which is placed in the center of
the detection coil for determining its magnetic permeability.
In their initial rep rt, Kriz et al. demonstrated detection of glucose by magnetic permeability
sensing [102]. Later, making use of a further developed me urement method, the authors
showed the detection of concanavalin A (ConA) protein by unspecific binding processes to the
particle surfaces [107]. Another demonstrated application concerns a one-step assay for measuring
C-reactive protein (CRP) in both human and canine samples for point-of-care applications [104,105].
Measurements of whole blood samples from 50 patients have been compared to results obtained
by different reference methods (a turbidimetric immunoassay a d two com ercially available PoC
instruments), an good correlation to the magnetic per e bility measurement method has been
reported [105]. The measurement method is well-suited for PoC testing due to its one-step assay
procedure and fast analysis time of only about 5.5 min [105]. Additionally, homogenous measurements
of CRP from whole blood canine samples have been carried out in comparison to ELISA reference
data [103]. Heterogeneous assay magnetic permeability measurements have been performed by
detecting unb und magnetic NPs after a filtration step and correlating their concentrati n to the
concentration of present CRP [106]. This assay has b en int g ated nto a port ble instrum nt that
can be applied for PoC sensing [106]. Quantitative agnetic permeability measurements have been
reported with a limit of detection (LoD) of 8 mg/L CRP, while reference ELISA reached a LoD of
3 mg/L [106]. Correlation analysis of the measured CRP biomarker concentrations in 47 canine serum
samples to a commercial ELISA kit resulted in an excellent coefficient of determination of 98%, and
the average values of about 6% for the intra- and inter-assay imprecision are also comparable to
commercial ELISA kits [106].
Homogeneous analysis of albumin in urine samples of 149 individuals by magnetic permeability
measurements has been reported by Lu et al. [108]. Albumin in urine serves as a protein biomarker
for diabetes and hypertension patients who have a higher risk for developing a nephropathy [108].
Comparisons with the results of a turbidimetric immunoassay that serves as the hospital’s reference
method show a good correlation with the magnetic permeability measurement results [108].
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Finally, a proof of principle for the detection of DNA has been reported by Abrahamsson et al. by
applying the magnetic permeability measurement method [109].
2.2. Detecting Variations of Hydrodynamic Properties of Magnetic Particle Labels
In this section, we discuss measurement methods for which the signal originates from changes in
the hydrodynamic properties of the magnetic particle labels following binding of analyte molecules.
Figure 2 illustrates magnetic particles with surface-immobilized recognition molecules (Figure 2a)
along with the two possible effects on the dispersion of the magnetic particles upon addition of analyte
molecules. Binding of analyte molecules always directly alters the hydrodynamic volumes of the
particles (Figure 2b), but can also lead to aggregation of magnetic particles into clusters in cases where
the analyte molecule has more than one epitope available for binding to the recognition elements
immobilized onto the particle surfaces (Figure 2c).
Sensors 2016, 16, 828 5 of 48 
2.2. Detecting Variations of Hydrodynamic Properties of Magnetic Particle Labels 
In this section, we discuss measurement methods for which the signal originates from changes 
in the hydrodynamic properties of the magnetic particle labels following binding of analyte molecules. 
Figure 2 illustrates magnetic particles with surface-immobilized recognition molecules (Figure 2a) 
along with the two possible effects on the dispersion of the magnetic particles upon addition of 
analyte molecules. Binding of analyte molecules always directly alters the hydrodynamic volumes of 
the particles (Figure 2b), but can also lead to aggregation of magnetic particles into clusters in cases 
where the analyte molecule has more than one epitope available for binding to the recognition 
elements immobilized onto the particle surfaces (Figure 2c). 
   
(a) (b) (c) 
Figure 2. Possible effects upon analyte molecule binding to magnetic particle labels: (a) Particles with 
immobilized recognition molecules on the surface; (b) Analyte molecules (red structure) bound to the 
particle surfaces increase the hydrodynamic volumes of the single particles; (c) Particle clustering 
induced by analyte molecule binding. 
Different methods and techniques are reported for measuring changes of the hydrodynamic 
properties of magnetic particle labels. The first approach involves aligning the magnetic particles in 
the direction of an external uniaxial static magnetic field and monitoring the time decay of the 
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particles with Néel relaxation times substantially larger than Brownian relaxation times, the recorded 
magnetization relaxation relates to the rotational diffusion of the particles back into their randomized 
state. The measured decay time depends on the actual hydrodynamic magnetic particle volume, 
which is altered on binding of analyte molecules. 
The second approach is based on dynamic agitation of the magnetic particle labels by external 
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measure the AC susceptibility of the magnetic particle label ensemble by analyzing frequency sweeps 
of the agitation field, methods based on a mixed-frequency detection approach, and methods that 
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sample as main parameter. 
The third approach is similar to the second one, but makes use of rotating magnetic fields instead 
of linear AC magnetic fields to agitate the magnetic particle labels (see Section 2.2.3). Studies making 
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Figure 2. Possible effects upon analyte molecule binding to magnetic particle labels: (a) Particles with
immobilized recognition molecules on the surface; (b) Analyte molecules (red structure) bound to
the particle surfaces increase the hydrodynamic volumes of the single particles; (c) Particle clustering
induced by analyte molecule binding.
Different methods and techniques are reported for measuring changes of the hydrodynamic
properties of magnetic particle labels. The first approach involves aligning the magnetic particles
in the direction of an external uniaxial static magnetic field and monitoring the time decay of the
sample’s mean magnetization after switching off the aligning field (see Section 2.2.1). For magnetic
particles with Néel relaxation times substantially larger than Brownian relaxation times, the recorded
magnetization relaxation relates to the rotational diffusion of the particles back into their randomized
state. The measured decay time depends on the actual hydrodynamic magnetic particle volume, which
is altered on binding of analyte molecules.
The second approach is based on dynamic agitation of the magnetic particle labels by external
linear AC magnetic fields (see Section 2.2.2). Here, we further distinguish between techniques that
measure the AC susceptibility of the magnetic particle label ensemble by analyzing frequency sweeps
of the agitation field, methods based on a mixed-frequency detection approach, and methods that
focus on studying the phase lag between the external magnetic field and the magnetization of the
sample as main parameter.
The third approach is similar to the second one, but makes use of rotating magnetic fields instead
of linear AC magnetic fields to agitate the magnetic particle labels (see Section 2.2.3). Studies making
use of this approach usually analyze the data with regard to the phase lag between the external
magnetic field and the magnetization of the sample.
In the following, we will discuss the measurement techniques particularly with regard to
their historical development and their potential application areas by giving examples of different
published bioassays.
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2.2.1. Magnetorelaxation Measurements
In an external magnetic field, the magnetic moments of particle labels dispersed in the sample
solution experience a magnetic torque, resulting in a net sample magnetization in field direction
governed by the Langevin equation [110]. Once the external field is switched off, the magnetic torque
vanishes, and the sample’s net magnetization relaxes back to zero. At the particle label scale, two
different relaxation processes can be distinguished, which are the Néel relaxation and Brownian
relaxation. Néel relaxation describes an internal decay of the magnetic moment of the particle labels,
while Brownian relaxation designates thermal rotational diffusion of the particle labels. Both processes
can be described by characteristic relaxation times.





with temperature T, the Boltzmann constant kB and a rotational drag coefficient ψ [111]. Here, the
latter in case of a spherical particle is given by:
ψ “ 6ηVh (3)
with the dynamic viscosity of the sample fluid η and the hydrodynamic NP volume Vh [111]. Thus, for





The dependence of the Brownian relaxation time on the hydrodynamic particle volume paves the
way for homogeneous biosensing applications, as particle clustering or binding of analyte molecules
induces changes in the relaxation times. This is schematically sketched in Figure 3a, which shows
the Brownian relaxation time plotted against the magnetic core diameter of a spherical NP. The NPs
applied for calculating the relaxation times comprise a magnetic core with a magnetic anisotropy
energy density K = 20 KJ/m3 (corresponding to magnetite Fe3O4) and a hydrodynamic shell around the
magnetic core of thickness t (indicated in Figure 3a by the grey area) [112]. Water at room temperature
is assumed as the sample medium. Obviously, large changes in particle volume resulting from particle
clustering induce substantial changes in the relaxation time that can be easily detected, while smaller
changes due to analyte molecule binding onto the particle surface have to be measured at a shorter time
scale. Moreover, it can be seen that an increase in hydrodynamic shell thickness induces changes of the
Brownian relaxation time for small particle core diameters only. Thus, for measurements of changes of
the hydrodynamic shell thickness upon binding of analyte molecules, small initial nanoprobes have to
be applied, while methods based on detecting particle agglomeration are less sensitive on the initial
nanoprobe size.
The Néel relaxation time τN is also called inverse flipping frequency of the magnetization and







where τ0 is usually in the range of 10´9 s, K is the particle’s magnetic anisotropy energy density, and
Vm denotes the particle’s magnetic volume [113].
Both relaxation times can be combined to an effective relaxation time τeff of the form [114]:
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Figure 3b shows both individual relaxation times and the effective relaxation time against the
magnetic particle core diameter. All parameters employed for the calculation are the same as applied
for the calculation of the Brownian relaxation time in Figure 3a, except that Figure 3b assumes
a hydrodynamic shell around the magnetic core of a constant thickness of 10 nm. Due to the
rapid increase of the Néel relaxation time with increasing magnetic volume, the Brownian relaxation
mechanism dominates for larger core diameters.
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Figure 3. Brownian, Néel and effective relaxation time in dependence of the particle volume.
A spherical magnetite particle with a magnetic core (purple area) encapsulated by a hydrodynamic
shell (grey area) of thickness t is assumed: (a) Brownian relaxation time in dependence of the magnetic
particle core diameter for hydrodynamic shell thicknesses of 10 nm (solid line) and 20 nm (dashed line).
While an increase of the hydrodynamic shell thickness affects the Brownian relaxation time of small
particles at short relaxation times, particle clustering induces large changes of the relaxation time less
dependent of the initial particle size; (b) Brownian, Néel and effective relaxation time as functions of
the magnetic core diameter [112].
Relaxation time determination has first been applied for biosensing in a heterogeneous
sandwich-type assay format making use of magnetic NP labels that bind specifically to a solid
surface via bound analyte molecules [115–119]. For the chosen NPs, the Brownian relaxation
time is substantially smaller than the response time of the superconducting quantum interference
device (SQUID) instrumentation applied to detect the sample magnetization. As the magnetic
moment of surface-bound magnetic NP labels can only relax by the slow Néel mechanism once
the external magnetizing field is switched off, only bound NP labels contribute to the signal, while the
magnetization of non-bound NP labels remaining freely in the sample solution has already decayed
via the fast Brownian relaxation mechanism. This measurement principle resulted in the development
of the so called magnetic relaxation immunoassay (MARIA), which is comparable to ELISA, but makes
use of magnetic NPs as labels instead of applying an enzymatic reaction for signal generation [120].
Here, Lange et al. showed detection of human immunoglobulin G (IgG) protein by employing a low
Tc-SQUID instrument and by measuring Néel relaxation. Furthermore, the remanence of the bound
magnetic NPs has been measured to deduce the analyte concentration as shown by Kötitz et al. [121].
Here, they applied functionalized magnetic NPs, which are bound to a flat surface via the analyte
molecule and measured the magnetization of the immobilized magnetic NPs to evaluate the analyte
concentration. For the measurement of the magnetic remanence, again a static magnetic field is applied
and the magnetization is observed over time with the difference that the sample is removed during
the measurement period so that the resulting change in the measured magnetization signal can be
related to the remanence of the fixed magnetic NPs. Unbound magnetic NPs are already relaxed in
their orientation by Brownian relaxation.
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Magnetorelaxation measurements (MRX, magnetorelaxometry) have also been applied to
homogeneous biosensing. For example, Kötitz et al. performed magnetic induction measurements
of the entire sample volume to record the relaxation signal of biotinylated iron oxide NP labels [112].
In this case, the signal is a mixture of both, Néel and Brownian relaxation, but as the Néel relaxation
time of the applied particle labels is substantially larger, the Brownian mechanism dominates. Thus,
measured changes in the relaxation time can be associated to changes in the hydrodynamic particle
volumes (see Equation (4)), which are induced by addition of avidin model analyte, thus inducing
particle label clustering [112]. Eberbeck et al. applied homogenous magnetorelaxometry to study
unspecific binding reaction kinetics of magnetic NPs onto latex micro beads and onto yeast cells [122].
This has later been expanded to specific binding reactions of the biotin-streptavidin model system
by coupling streptavidin and anti-biotin antibody functionalized magnetic NPs to biotinylated micro
agarose beads [123]. Yang et al. also employed the biotin-avidin model system to evaluate the
amount of avidin added to a solution of biotinylated magnetic NP labels, which caused clustering
of the particles and, consequently, a change in the measured relaxation time [124]. Studies of the
Brownian magnetization relaxation curves measured homogeneously for magnetic particle labels
has also been performed by Enpuku et al., who showed detection of Candida albicans fungi [125].
Specifically, they applied a sandwich-type assay making use of biotinylated antibodies to target the
fungi and avidin-coated magnetic NPs that bind to the biotinylated antibodies [125]. Contrary to the
short relaxation times of unbound magnetic markers of about 0.4 ms, particles immobilized onto fungi
show an increased relaxation time of about 24,000 ms due to the fungi size [125]. The same group
established similar bioassays based on analyte molecule induced binding of magnetic NPs to polymer
microbeads [126]. By using this measurement technique, biotin model analyte has been detected down
to a concentration of 0.95 fM [127]. Another possible application of the magnetorelaxometry technique
is the quantification of the uptake of magnetic NPs by cells [128].
MRX measurements have also been performed by applying fluxgate magnetometers, which offer
the possibility to make use of miniaturized measurement instruments applicable to point-of-care
settings. This is hardly possible for SQUID magnetometers, which require extensive hardware for
cooling. Ludwig et al. applied fluxgate magnetometers to study the relaxation behavior of magnetic
particle labels [129]. The same group improved the detection technique by making use of two fluxgates
in a differential configuration, which allows to perform measurements in a magnetically unshielded
environment [130]. A homogeneous MRX bioassay making use of fluxgate magnetometers was
demonstrated for the study of binding reactions of streptavidin functionalized magnetic NP labels to
biotinylated agarose microbeads and to biotinylated bovine serum albumin (BSA) protein [131].
2.2.2. Dynamic Agitation by Linear AC Magnetic Fields
The biosensing principles discussed in this section are based on analyzing the frequency
dependence of the sample’s magnetic susceptibility. For sufficiently small amplitudes, the induced
magnetization of a sample fluid containing magnetic particle labels is a linear function of the
magnetizing field strength, and it can be characterized by the complex magnetic susceptibility
χ = χ’ ´ iχ”. The dependence of the susceptibility on the frequency of the external field is given by:
χ pωq “
χ0
1` iωτe f f
(7)
with the angular frequency ω, the corresponding susceptibility in an external DC magnetic field χ0,
and the effective relaxation time τeff [132]. The real (Equation (8)) and the imaginary (Equation (9))














These formulas indicate that the real part of the magnetic susceptibility decreases with increasing
frequency, while the imaginary part shows a maximum at ωτeff = 1, which allows to deduce the
Brownian relaxation time and, consequently, the hydrodynamic particle volume (see Equations (4) and
(6)) [132]. Plots of both parts of the magnetic susceptibility χ are shown in Figure 4 against ωτeff with
ω = 2πf and the magnetic excitation field frequency f.
An alternative representation of the AC susceptibility measurement signal is given by the phase lag
ϕ, which is a measure of the phase between the exciting external magnetic field and the magnetization








Different measurement approaches have been employed in the literature to detect changes of
the hydrodynamic particle properties by dynamic linear AC magnetic field excitation, which will be
discussed in the following subsections.
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Figure 4. Relative magnetic suscepti ilit /χ0 in depe d nce of ωτeff. The real and the im ginary
part of the magnetic susceptibility are plotted against the product of the angular frequency of the
magnetic excitation field ω and the effective relaxation time τeff. The maximum of the imaginary part
χ2 occurs at ωτeff = 1. An effective relaxation time of 50 µs is assumed.
Frequency Sweep AC Susceptibility Measurements
These types of methods are based on m asuring he imped nce of an in uction coil into which
a vial cont i ing the sampl fluid with dded magnetic particle labels is placed [132]. To that end,
the magnetic particles are excited by an external linear AC magnetic field of variable frequency
generated by the induction coil [132]. While the coil’s inductance depends on the real part of the
sample’s susceptibility, the coil’s resistance is directly related to the imaginary susceptibility part of
the sample [132]. By analyzing frequency sweeps of the applied AC magnetic field, changes of the
measured complex susceptibility of the sample can be directly related to the hydrodynamic volume of
the magnetic particle labels and, thus, to the binding of analyte molecules.
Some applications of this method to biosensing have been presented by Astalan et al. and by
Chung et al. The former group verified the sensor principle by detecting prostate specific antigen
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(PSA) in buffer solutions employing magnetite NPs labels functionalized by specific antibodies [134].
The latter group demonstrated binding reactions of biotinylated S-protein to avidin functionalized
magnetite NP labels [135,136]. AC susceptibility measurements have also been shown by employing
cobalt NPs dispersed in water as labels [137].
Fornara et al. presented the synthesis of magnetite single core NPs with optimized performance for
AC susceptibility measurements [138]. Following functionalization of the magnetic NPs, the authors
could show detection of specific antibodies in untreated serum samples of cows infected by Brucella
bacteria with a limit of detection of about 0.05 µg/mL of Brucella antibodies [138].
Further AC susceptibility biosensing-related studies include the analysis of binding reactions
of avidin-coated iron oxide magnetic NP labels with biotin-coated polymer microbeads to gain
information on size distributions of the magnetic particle labels, the signal’s dependence on the
concentration of the applied polymer particles and the effect of different incubation times [139–141].
The AC susceptibility measurement method has also been applied to the detection of DNA by
the so called “volume-amplified magnetic nanobead detection assay”. It has been shown that specific
DNA strands can be detected following rolling circle amplification steps [142]. This technique has
been extended to multiplexed detection of DNA sequences [143] and was also adopted into portable
measurement instruments [144]. It has been applied to detect Bacillus globigii spores [145] and bacterial
DNA originating from Vibrio cholerae and Escherichia coli (E. coli) [146].
In addition, AC susceptibility biosensing can also be carried out in a multiplexed format by
making use of the distinct spectral positions of the imaginary part of the complex susceptibility of
differently sized magnetic particle labels, thus enabling simultaneous detection of different types of
analyte molecules within the same sample solution [147].
Öisjöen et al. studied the increase of the hydrodynamic volume of magnetic NP labels upon
analyte molecule binding by analyzing AC susceptibility frequency sweeps in combination with
magnetorelaxation measurements, i.e., monitoring of the decay of the sample’s magnetization after
an aligning magnetic field is switched off [148]. While data fits to AC susceptibility spectra reveal the
actual size distribution of the applied magnetic particle labels, the magnetorelaxation data allows to
observe real-time kinetics of binding events. Both measurements are done by making use of a SQUID
magnetometer, and a LoD of 10 µg/mL of the applied streptavidin-coated multi-core CoFe2O4 magnetic
particle labels was obtained [148]. As model analyte, the authors employed PSA targeting biotinylated
antibodies and demonstrated a LoD of 0.7 nM [148].
Mixed-Frequency AC Susceptibility Measurements
A change in the dynamics of magnetic particle labels upon an increase in hydrodynamic
volume can also be measured by the magnetic susceptibility reduction method. Here, the magnetic
susceptibility of the sample reduces upon analyte molecule binding due to the growing hydrodynamic
volume or clustering of the magnetic particle labels. The immunomagnetic reduction (IMR) method is
based on detecting this reduced susceptibility by applying a mixed-frequency read-out technique [149].
To that end, the magnetic particle labels are excited by two linear AC magnetic fields of
different frequency, which are generated by two distinct excitation coils (see Figure 5a for a schematic
measurement setup) [149]. The measurement signal is the sample’s magnetization, which is detected by
a pick-up coil [149,150] or, for higher sensitivity, by a SQUID magnetometer [151,152]. The excitation
frequencies are chosen high enough, so that only single magnetic particle labels can follow, while
clusters of magnetic particle labels are not affected. Therefore, the measured susceptibility originates
from single particles only [149]. The reduction in measurement signal can be directly related to the
amount of bound analyte molecules [149,150]. Applying an excitation mode with two different
frequencies f1 and f2 allows to detect the magnetic susceptibility χAC not only at the excitation
frequencies but also at mixed frequencies of the form mf1 + nf2 with integers for m and n [149].
This leads to an improved signal-to-background ratio as the single excitation frequencies are effectively
suppressed from the measurement signal [149]. Bioassay measurement based on this method have
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been reported by Hong et al., who showed detection of CRP in serum samples [150]. The same group
further developed the IMR technique by employing a SQUID-based measurement setup for more
sensitive detection of magnetic particle labels, and they achieved a CRP limit of detection of 10´6 mg/L,
which presents an improvement in sensitivity of five orders of magnitude compared to their previous
publication [150,151]. The group has also shown that the dependence of the detected signal on the
analyte molecule concentration follows a logistic function (see Figure 5b) [152], which is discussed in
more detail in a separate publication [153]. The logistic function is commonly applied as a valuable
tool for the interpretation of IMR measurement results.
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Recent publications have demonstrated the feasibility of the IMR method for the detection of
different protei s in clinically rel vant settings. Here, examples inclu e the detection of CRP in buffer
and in h man serum samples [154] r the detecti n of the insulin-like growth fact r binding protein-1
(IGF-1) in cervicovaginal secretions of pregnant women for the diagnosis of preterm premature rupture
of membranes [155]. Molecular diagnosis of cancer by detecting protein biomarkers in serum samples
has been reported for the des-γ-carboxyprothrombin protein in rat serum, and it was shown that the
concentration of the protein biomarker correlates with the tumor size in hepatocellular carcinoma [156].
Furthermore, the concentration of the α-fetoprotein (AFP) was evaluated in human serum samples of
both healthy individuals and patients with liver tumors [157]. Finally, the vascular endothelial growth
factor protein has been mployed s analyte molecule in human serum for the distinction of healthy
individuals a d tumor patients with colorectal or h patocellular cancer [158,159].
Specific proteins lik β-amyloid-40 (Aβ-40), Aβ-42 and the tau-protein serve as the most
prominent biomarkers for research on Alzheimer’s disease and mild cognitive impairment. IMR
measurements of these proteins in buffer solutions [160,161] to give a first proof-of-principle have been
reported and previously the detection has been shown in human plasma samples [159,160,162–164].
In addition to proteins, IMR has also been applied for the sensing of small molecules like
hormones, as it has been reported by Chen et al. for the detection of the β-subunit of human chorionic
gonadotropin in urine samples of pregnant women [165]. Furthermore, a general proof for the
successful detection of DNA by IMR measurements can be fou in th publication of Yang et al. [166].
Moreover, IMR has been reported for virus bioassays as well. Examples include the detection of
two types of orchid viruses by m gnetic NP labels functionalized by an antibody to target the virus
particles [167], the detection of the avian virus H5N1 [168], and swine influenza A viruses [169].
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Finally, the IMR measurement technique has been employed in the field of veterinary research
and for food control. Specifically, an assay for detecting shrimp white spot disease caused by white
spot syndrome virus [170] has been developed, and the detection of antibiotics in shrimp has been
achieved by direct binding of the chloramphenicol drug to antibodies on the particle label surface [171].
Additionally, an IMR assay has been developed for sensing of the nervous necrosis virus extracted
from aquaculture groupers [172,173].
Phase Lag AC Susceptibility Measurements
An alternative approach for analyzing the dynamics of magnetic particle labels is to examine
the phase lag between the AC magnetic excitation field and the magnetization of the sample fluid
(see Equation (10)), which allows detecting the signal of interest at a single frequency. Liao et al.
introduced this measurement mode employing dextran-coated superparamagnetic Fe3O4 particles
with core diameters of 12 nm as magnetic particle labels [174]. For bioassay measurements, the applied
particles were functionalized by antibodies targeting the CRP protein, and particle clustering was
induced by CRP analyte [174]. Particle clustering affects the total effective relaxation time and, thus,
the AC susceptibility and the measured phase lag [174]. Liao et al. demonstrated CRP detection down
to approximately 40 nM in buffer solution [174]. The same group also examined detection of AFP in
buffer solution and obtained a LoD of about 1 nM [175]. Excitation and detection is experimentally
realized by a respective coil arrangement, and a Lock-In amplifier is employed for the phase lag
determination [174,175]. Here, the observed phase lag differences upon analyte addition with respect
to samples without analyte molecules reach about 0.3–2˝, while the absolute phase lags amount to
about 3˝ [174,175].
Tu et al. developed a measurement mode which combines the mixed-frequency detection
technique as discussed above with observations of the phase lag between the magnetization of
the sample and the external magnetic field [176]. Specifically, the magnetic particle labels are
simultaneously excited by two linear magnetic fields of different frequency, and the signal to be
detected is the phase lag of the resulting sample magnetization with respect to the excitation fields.
In their experiments, one frequency is kept fixed, while the other frequency is scanned, and the phase
lag is recorded in dependence of the variable frequency [176].
2.2.3. Dynamic Agitation by Rotating Magnetic Fields
Instead of applying linear AC magnetic fields, actuation of the magnetic particle labels can also be
achieved by applying rotating magnetic fields. It has been shown that rotating magnetic field actuation
leads to higher signal values compared to linear AC magnetic field actuation [133]. As described in the
previous section, the hydrodynamic properties of the particle labels can be represented by the phase lag
of the sample magnetization to the applied magnetic field. A schematic illustration of the measurement
method is shown in Figure 6. When the Néel relaxation time of the applied magnetic particle labels
is substantially larger than the period of the exciting rotating magnetic field, the magnetic particle
moment follows the rotating magnetic field by Brownian rotation. Due to the hydrodynamic drag the
particle label experiences within the sample fluid, this rotation is delayed by a steady-state phase lag
ϕ, which rises when the hydrodynamic diameter dhydro of the particle label increases due to binding of
analyte molecules.
A first proof-of-principle of magnetic particle label agitation by rotating magnetic fields and
magnetic detection by fluxgate magnetometers has been given by Dieckhoff et al. [177]. The authors
demonstrated detection of binding processes of IgG antibodies to magnetic NP labels functionalized
by protein G and analyzed the dependence of the measurement signal on the analyte molecule
concentration [178]. It has also been reported that the binding kinetics of analyte molecules to the
magnetic NP labels can be interpreted according to the law of mass [179]. Absolute phase lag values of
up to 60˝ and phase lag differences between samples with and without added analyte molecules of up
to 20˝ were observed [179].
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Figure 6. Schematic illustration of the phase lag ϕ as measure t i nal for magnetic particle labels
with dominating Brownian relaxation behavior excited by a rot agnetic field. The magnetic
moments of the particle labels lag behind the applied rotating magnetic field by a phase lag ϕ, which
depends on the hydrodynamic NP diameter dhydro. A change in dhydro upon analyte molecule binding
causes an increase of the measured phase lag.
2.3. Nuclear Magnetic Resonance Measurements
Nuclear magnetic resonance (NMR) measurements of water protons in conjunction with magnetic
particles can be applied for biosensing of a variety of different analytes, as will be shown in the
following. Usually, superparamagnetic NPs are employed to modify the precession of the nuclear
spins of water protons in the proximity of the NPs, which in turn alters the measured relaxation
times [180–185], but application of paramagnetic particles has also been reported [186].
Adding superparamagnetic NPs to samples that are measured by NMR leads to the creation of
local magnetic dipole fields that cause inhomogeneities of the applied external static magnetic field,
which results in differences of nuclear spin precession of protons close to the NPs and protons
of the bulk sample material (dephasing of proton spins) [180–184]. An important property of
superparamagnetic NPs employed for NMR measurements is their relaxivity, which is defined as
their capacity to alter the relaxation rate constants, both longitudinal (parallel to the external static
magnetic field) and transverse (perpendicular to the external static magnetic field) [187]. The relaxivity
depends of the single NP size and the concentration of the NP ensemble [181,187]. The relaxation
rate constants are inverse functions of the relaxation times (R = 1/T), so that the relaxivity directly
correlates to changes of the relaxation times and, thus, to the signal enhancement achieved by the
employed magnetic NPs [180–182,184,187,188]. The time associated to transverse relaxivity is denoted
as T2, and T1 is associated to the longitudinal relaxivity [187].
As the longitudinal relaxivity is smaller than the transverse relaxivity for commonly employed
magnetic NPs, measurements of the latter are usually employed for biosensing [181,184]. This way,
lower concentrations of magnetic NPs need to be applied, which increases the assay’s sensitivity and
lowers the amount of required reagents [181,184].
If the NPs are functionalized to bind to specific target molecules, two distinct measurement modes
can be applied for biosensing, as described below [181,184].
In the first measurement mode, the biomarkers of interest are labeled by the magnetic NPs,
and the excess of unbound NPs is removed [181,184]. The remaining NPs induce changes of the
sample’s relaxation times due to the added magnetic field inhomogeneities, which are proportional
to the number of residual magnetic NPs [181,184]. This measurement mode is used for detecting
larger targets like cells and bacteria, which can easily be separated mechanically from unbound free
NPs [181,184]. In those cases, the magnetic NPs bind to biomarkers on the cell surface [184].
The second measurement mode relies on clustering of the magnetic NPs due to cross-linking
by analyte molecules that specifically bind to the functional groups immobilized onto the
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NP surfaces [181,184]. A difference of the T2 relaxation time between single-dispersed NPs
and agglomerated NPs is the fundamental effect on which this measurement approach is
based [180–182,184,189]. Applications of this method include the sensing of small molecules (e.g.,
drugs), oligonucleotides and proteins [181,184]. By using enzymes, competitive binding processes
or changes of the pH value and of the temperature, the assay can be performed backwards as well,
i.e., starting from particle agglomerates and ending at single-dispersed particles [181,182,190]. This
dual-direction biosensing capability is termed magnetic relaxation switching (MRSw), which describes
changes of the organizational state (single-dispersed vs. agglomerated) of the magnetic NPs in
solution [181,182,184]. The principle of the MRSw measurement method is sketched in Figure 7 [191].
The formation of magnetic NP agglomerates results in a decrease of the measured relaxation time, and
vice versa if particle agglomerates are dispersed into single NPs.
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Figure 7. Schematic principle of the magnetic relaxation switch (MRSw) measurement method.
Single-dispersed magnetic NPs can cross-link to form NP agglomerates, which results in a shortening of
the transversal relaxation time T2. Vice versa, unbinding processes starting from particle agglomerates
and resulting in single-dispersed NPs increase the me sured relaxation time. While inding of NPs can
be caused by the analyte of interest itself, unbinding may result fro an addition of suitable enzymes,
competitive binding processes or changes of the pH value and of the temperature. Raw signals of NMR
measurements are shown at the bottom to illustrate the different relaxation times (indicated by the red
dotted lines). Modified graph reprinted from Lee et al., [191] by permission from Macmillan Publishers
Ltd., copyright 2008.
The observation of reduced relaxation times upon magnetic NP agglomeration can be explained
by the outer-sphere theory. General comprehensive summaries of the outer-sphere theory can be found
in [180–182,184], while a more detailed description is given in the [192–194]. Briefly summarized,
the relaxivity is directly proportional to the geometric cross section of the NP [181]. Additionally,
a particle cluster consisting of single NPs can be seen as an equivalent of an enlarged single NP,
which has been shown to be true regardless of the cluster’s fractal dimension [180,182]. Thus, the
formation of a NP cluster can be described by a single NP of increasing size, which means that upon
NP agglomeration, the relaxivity increases and the measured relaxation time decreases [180,182]. Here,
the effective cross section of a NP agglomerate is larger than the sum of the contributing single NPs
up to a certain limit of agglomerate size (>100 nm diameter) [180,182]. The relaxivity increases with
agglomerate size up to a plateau, which is then followed by a decrease [180]. The decrease in relaxivity
can be explained qualitatively by the increasing distance between NP agglomerates so that less water
protons are affected by the generated magnetic field inhomogeneities, which is related to the limited
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translational diffusion behavior of water molecules during the time scale of a MRSw experiment (less
protons diffuse into the inhomogeneous regions of the static magnetic field within the duration of
an experiment) [182]. A detailed introduction and also an extension of the outer-sphere theory is
given in [180]. Furthermore, a set of mathematical equations that allow to model the behavior of
MRSw experiments and to calculate assay sensitivities and dynamic ranges has been published by
Min et al. [190].
A wide range of different applications of NMR measurements making use of superparamagnetic
NPs can be found in literature and is already partly listed in [180–185]. The following paragraphs give
an introduction into the broad area of potential applications.
Josephson, Perez and Weissleder have been the first ones who discovered the biosensing potential
of NMR measurements assisted by superparamagnetic NPs [195]. Here, they employed oligonucleotide
functionalized NPs, which were cross-linked by complementary oligonucleotide strands to induce NP
clustering, thus leading to a decrease of the observed transversal relaxation time [195]. The backward
direction of the MRSw sensing approach has first been demonstrated by Perez et al., who showed that
the transversal relaxation time increases when NPs connected by double stranded DNA are separated
from each other by applying DNA-cleaving agents [196,197]. NMR measurements have also been
used to detect polymerase chain reaction (PCR) products [198–200], which has been applied for the
diagnosis of tuberculosis [199].
The first experimental results on the detection of protein-protein interactions by applying green
fluorescent protein antibody functionalized NPs to detect the corresponding proteins have been
presented by Perez et al., who in the same publication also presented results on enzyme activity
sensing achieved by reversing the MRSw assay direction (enzymatic cleaving of NP binding to yield
single-dispersed NPs in solution) [197]. Additionally, several enzymes have been tested by applying
the MRSw sensing principle. Exemplary, avidin functionalized NPs can be cross-linked by applying
a bi-biotinylated peptide, which in the following can be cleaved by the protease enzyme to generate
a change in measured relaxation time [201]. Other examples are lysozymes, which have been tested
in human serum samples with a LoD in the lower nanomolar regime [202], and measurements of
the telomerase activity by employing different telomerase inhibitors [203]. Measurements of the T2
relaxation time by nuclear magnetic resonance have also been applied for determining dissociation
constants between proteins and associated ligands [204].
Larger molecules have also been examined, e.g., viral particles of the herpes simplex virus and the
adenovirus [205], S. enterica bacteria in milk samples [206] or cancer cells that have been detected and
profiled by MRSw sensing [207]. On the other end of the scale bar, also very small molecules have been
detected in various sample solutions. For example, hormone-like bisphenol A molecules have been
tested in drinking water with a LoD of 400 pg/mL [208], enantiomeric impurities in solutions of the
amino acid phenylalanine have been examined [209], and the salbutamol drug has been measured in
swine urine samples [210]. Identification of inhibitors for toxins released by the Anthrax bacterium by
measurements of the T2 relaxation time has also been reported [211]. In a suitable measurement setting,
MRSw can also be applied to detect ions in solution, which has been shown by Atanasijevic et al., who
detected calcium ions by applying calcium dependent protein-protein interactions to induce magnetic
NP agglomeration [212].
Further developments of the measurement principle concern miniaturization of the experimental
setup [191,213,214] and the development of implantable MRSw systems, which have been tested up to
now for the detection of both cancer and cardiac biomarkers [215–217].
3. Optical Detection Methods
In this section, we review biosensor concepts that rely on magnetic agitation and optical detection
of magnetic particles. Optical detection has the advantage that the distance between the sample and the
detector usually is not a very crucial parameter (especially when measuring in transmission geometry),
whereas the fast decay of the particle’s magnetic stray field with distance usually requires close
proximity of the detector to the sample for magnetic detection methods, which limits the flexibility in
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the design of biosensing setups. In addition, by spectral tuning of the optical response of the particle
labels, multiplex analyte detection formats can be designed [218]. Optical detection of magnetically
induced orientation changes of the particles in the sample solution requires that the particles display
some sort of optical anisotropy, which can be the result of either clustering of intrinsically optically
isotropic particles (see Section 3.1), or can follow from an intrinsic optical anisotropy of the particles
(see Section 3.2).
3.1. Detection by Clustering of Intrinsically Optically Isotropic Magnetic Particles
In this section, we discuss biosensing concepts where optical detection of the particles relies on
an optical anisotropy that is induced by assembly of initially optically isotropic particles into doublets,
chains or clusters. When these particle assemblies are agitated by an applied magnetic field, their
optical signal is modulated, which allows to quantify the concentration and the average size of the
magnetic particle clusters.
3.1.1. Sandwich Assays on Magnetically Rotated Particle Clusters
In an applied magnetic field, the magnetic moment of individual particle labels aligns in field
direction, and the magnetic dipolar interaction between particles can lead to formation of particle
chains along the field lines. In this way, it is possible to conduct standard sandwich immunoassays on
the surface of the magnetic particles and read out analyte concentration dependent signals directly in
the sample solution without requiring washing. The concept was introduced by Anker et al. and is
sketched in Figure 8 [219]. The observed fluorescence intensity of fluorophores bound to the surfaces of
the magnetic particles can be modulated by varying the orientation of the particle chains by the applied
magnetic field, which changes the relative number of visible (dark stars in Figure 8) to non-visible (light
stars in Figure 8) fluorophores. In a demonstration experiment, Anker et al. applied biotin-labeled
fluorophores directly to streptavidin-coated magnetic particles (870 nm mean diameter by Bangs
Laboratories Inc., Fishers, IN, USA), and could demonstrate the detection of bound fluorophores above
the large background of unbound labels by magnetic modulation [219].
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A similar demonstration experiment was later carried out by Petkus et al., who showed detection 
of fluorophore-labeled cortisol analyte by magnetic particles (1.6 µm mean diameter BioMag particles 
by Polysciences Inc., Warrington, PA, USA) functionalized by monoclonal cortisol antibodies [220]. 
They could achieve a cortisol detection limit of 300 pM in buffer solution by magnetically rotating 
particle clusters and analyzing the modulated fluorescent intensity by a lock-in amplifier [220]. They 
later extended their analysis to the cardiac protein biomarker myglobin, and compared immunoassays 
both in competitive and sandwich (non-competitive) format performed in buffer and serum [221]. 
They achieved similar detection limits in buffer and serum of about 2.5 nM for the competitive format, 
and about 50 pM for the sandwich format [221]. Here, however, the only assay that was performed 
strictly without any washing step was the competitive format type assay in buffer, while all other 
experiments included at least one washing step [221]. This is also true for the most recent study by 
Figure 8. Sketch of an immunoassay performed on chains of magnetic particles induced by an externally
applied magnetic field. The observed fluorescence intensity depe s on the relative number of visible
(dark stars) versus non-visible (light stars) flu rophores bound o the magnetic particles, wh ch can be
modified by varying the orientation of the applied magnetic field (On and Off state). Modified graph
reprinted with permission from [219]. Copyright 2003, AIP Publishing LLC.
A similar demonstration experiment was later carr ed out by Petkus et al., who showed detection
of fluorophore-labeled cortisol analyte by magnetic particles (1.6 µm mean diameter BioMag particles
by Polysciences Inc., Warrington, PA, USA) functionalized by monoclonal cortisol antibodies [220].
They could achieve a cortisol detection limit of 300 pM in buffer solution by magnetically rotating
particle clusters and analyzing the modulated fluorescent intensity by a lock-in amplifier [220]. They
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later extended their analysis to the cardiac protein biomarker myglobin, and compared immunoassays
both in competitive and sandwich (non-competitive) format performed in buffer and serum [221].
They achieved similar detection limits in buffer and serum of about 2.5 nM for the competitive format,
and about 50 pM for the sandwich format [221]. Here, however, the only assay that was performed
strictly without any washing step was the competitive format type assay in buffer, while all other
experiments included at least one washing step [221]. This is also true for the most recent study by the
group, where following further refinement of their image analysis procedure [222], they demonstrate
highly sensitive detection of three cardiac biomarkers (detection limits: myoglobin ~360 aM, heart-type
fatty acid binding protein (H-FABP) ~67 fM, troponin I ~42 fM) [223]. The biomarkers are spiked into
buffer solutions and are detected by a sandwich immunoassay format performed on magnetically
rotated particle clusters [223].
In summary, while immunoassays on magnetically rotated particle clusters can be in principle
applied in a strictly homogeneous format [221], up to now the most sensitive results do involve
washing steps [223], and it has yet to be demonstrated that the method can also be performed directly
in unprocessed sample material with sufficient sensitivity and specificity.
3.1.2. Particle Clustering Mediated by Analyte Molecule Binding
Another approach of using magnetic particle clustering is to induce binding between magnetic
particles in an external magnetic field via bound analyte molecules, thus creating particle doublets,
multiplets, chains or clusters that are also retained once an applied magnetic field is removed
again. Here, a prerequisite is that the analyte molecule possesses multiple binding sites to receptors
immobilized onto the magnetic particles, thus enabling cluster-formation of particles. If this is not
the case, as usually encountered for small molecule detection, a competitive assay format can also be
chosen where clustering of particles is reduced by analyte interaction (see [224], for example). In the
following, different concepts are presented which are based on optical detection of analyte-specific
clustering of magnetic particles that make use of magnetic fields to accelerate cluster formation and/or
to induce periodic variations in the optical signal.
Detection of Magnetically Accelerated Particle Dimer Formation
The most basic realization of particle clustering mediated by analyte molecule binding was
introduced by Baudry et al. and is sketched in Figure 9 [225]. It is based on optical density
measurements of magnetic particle dispersions functionalized by either polyclonal or two different
types of monoclonal antibodies against the target antigen. The antigens are then captured at the
surfaces of the particles, and the formation of particle chains in an applied magnetic field accelerates
the creation of particle doublets via bound analyte molecules, which are also retained once the magnetic
field is switched off again. As particle doublets scatter light differently than two single particles, the
concentration of dimers, and, thus, analyte molecules can be quantified by turbidimetric (extinction)
measurements [225]. In an initial demonstration experiment, Baudry et al. showed a detection limit of
about 1 pM for ovalbumin model analyte in buffer by magnetic particle labels (200 nm diameter by
Ademtech SA, Pessac, France) functionalized by polyclonal ovalbumin antibodies with a total cycle
time of five minutes, which includes application of a 20 mT strong magnetic field for one minute to
accelerate dimer formation [225]. From experiments without the magnetic field incubation step, the
authors extrapolate that achieving the same density of dimers without magnetic field acceleration
would take more than eight hours [225]. Thus, compared to long-established similar immunoassays
based on agglomeration of latex particles [226], the magnetic agitation step makes this simple method
both fast and sensitive. Following detailed analysis of the theory of ligand-receptor interaction in chains
of magnetic particles [227] and experimental investigations of the kinetics for analyte molecules with
different tether lengths and numbers of binding sites [228], the group also demonstrated the method
to be capable of detecting C-reactive protein (CRP) directly from serum samples with a detection
limit of about 1 pM and a dynamic range of three orders of magnitude with a total cycle time of
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one minute [229]. Finally, the group also introduced an advanced measurement method, where the
concentration of dimers is no longer determined in a randomized state, but the extinction difference
of the dimers for magnetic-field induced alignment parallel and perpendicular to the optical axis is
used, which further increases the signal and achievable sensitivity [230]. Here, the trick is to apply the
aligning magnetic field pulse at a magnitude sufficient to rotate the particle doublets created by analyte
molecule interaction in the field direction, but insufficient to induce re-chaining of particle labels by
magnetic dipolar interactions, which would lead to a false unspecific signal [230]. For their chosen
experimental conditions, the authors determined a field magnitude of 5 mT as good compromise
between particle doublet alignment rate and prevention of re-chaining [230].
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a mean diameter of 250 nm, Park et al. demonstrated this method for direct one-step detection of the 
model analyte avidin with a detection limit of about 100 pM within a measurement time of less than 
30 s [231]. While detection of actual biomarkers in real samples still needs to be demonstrated, this 
method represents a fast and simple homogeneous analysis of biomarkers. 
Figure 9. Sketch of analyte detection by magnetically accelerated particle dimer formation. Antigen
analyte is captured by magnetic particles functionalized by either polyclonal or two different types
of monoclonal antibodies, and under the action of an externally applied magnetic field, the particles
assemble in chains, thu acc lerating the formation of particle doublets via bound antigen. Once the
magnetic field is turne off again, the doublets remain stable due to the bound a alyte, and the
concentration of doublets versus single magnetic particles can be quantified by turbidimetric (extinction)
measurements. Reprinted with permission from [225]. Copyright (2006) National Academy of
Sciences, USA.
Magnetically Rotated Par icle Chain Detection
A similar measurement method as described by Baudry et al. [225] has been introduced by
Park et al. [231], but i stead of follow ng a multi- tage protocol, they carry out a one-step procedure
that comprises continuous application of a rotating magnetic field (RMF) [231]. Here, the RMF induces
formation of magnetic particle chains that follow the applied field rotation, which also leads to
modulation of the transmitted light intensity (see Figure 10a) [231]. The length of the particle chains is
limited by the balance betwe n the hydrodynamic fo ce due to t e viscosity of the solution and the
total strength of the attractive force between the particles. For particles with bound analyte molecules,
their binding strength adds to the attractive magnetic dipolar interaction force between particles,
thus leading to an increasing average particle chain length ith analyte olecule concentration (see
Figure 10b) [231]. As the modulation intensity of th tr nsmitted light also depends on the average
length of the rotating particle chains, the a plitude of the trans itted light intensity is a measure of
the analyte concentration in the sample solution [231]. Applying biotinylated magnetic particles with
a mean diameter of 250 nm, Park et al. demonstrated this method for direct one-step detection of the
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model analyte avidin with a detection limit of about 100 pM within a measurement time of less than
30 s [231]. While detection of actual biomarkers in real samples still needs to be demonstrated, this
method represents a fast and simple homogeneous analysis of biomarkers.Sensors 2016, 16, 828 19 of 48 
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Figure 10. Sketch of analyte detection by magnetically rotated particle chains. (a) The transmitted
light intensity depends on the orientation of the magnetic particle chains, which can be modified
by the direction of the applied magnetic field; (b) When the magnetic field is rotated, the magnetic
particle chains follow the rotating magnetic field. The medium length of the magnetic particle chains
depends on the strength of the attractive force (Fattract) between individual particles, which is stronger
for analyte-carrying particles due to the binding strength FABC, which adds to the magnetic dipolar
interaction Fm. As the magn tic parti le chain length also influences the l tion intensity of the
transmit ed light when the particle chains ar rotated, the tran mitted light modulation is indicative of
the concentration of analyte molecules in the sample solution. Reprinted with permission from [231].
Copyright 2010, American Chemical Society.
Scattering D tection of Particle Cluster Magneto tation
The principal multi-step measurement procedure introduced by Baudry et al. [225], which
comprises incubation of the samples with functionalized magnetic particle labels, acceleration of
particle clustering via bound analyte molecules by inducing chain formation in an applied magnetic
field and optical detection of the formed parti le cl sters, has bee refined with regard to the final
detectio step by Ranzo i et al. [232]. While the quantity of interest, which is the conc ntration
of particle clusters, is measured above a large background signal of non-agglomerated particles by
the extinction measurements performed by Baudry et al. [225], Ranzoni et al. introduced a method
specific to particle clusters based on scattering measurements in a rotating magnetic field (RMF) [232].
Figure 11 shows a sketch of their measurement setup, where the optical path is along the z-axis,
the RMF is applied in the xz-plane, and the scattered light is picked up at an angle of ~30˝ from
the z-axis. Due to their characteristic magnetic and optical anisotropy, particle doublets rotate with
the applied magnetic field and induce a modulation of the scattered light intensity at twice the
frequency of the RMF, while the contribution of single particles to e optical signal modulation is
negligible [232]. The measurem nt signal represents the magnitude of the 2nd harmonic of the optical
scattering intensity as analyzed by fast Fourier transformation (FFT). When the frequency of the
RMF is increased, the particle doublets first follow the RMF synchronously with increasing phase
lag up to a critical frequency, which is defined by equal magnetic and drag torques, while at higher
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frequencies, alternating forward and backward rotations of the doublets occur [233]. By analyzing the
resulting frequency dependence of the particle magnetorotation, Ranzoni et al. demonstrated direct
quantification of the concentrations of particle doublets as well as the average values and variations
of the magnetic susceptibilities of magnetic particles (particles with mean diameters of 300 nm and
500 nm by Ademtech SA, Pessac, France) [232]. To demonstrate the applicability of their method for
homogeneous biosensing, they carried out detection of spiked biotinylated bovine serum albumin
(BSA) model analyte by streptavidin functionalized particle labels and showed a detection limit of
about 400 fM in buffer and 5 pM in plasma [232]. By optimizing the molecular surface architecture
of the magnetic label antibody functionalization, the group could also demonstrate detection of the
cancer biomarker prostate-specific antigen (PSA) directly in blood plasma, achieving hereby a detection
limit of about 500 fM for a total assay time of 14 min (160 fM in buffer) [234]. In the analysis of the
measured analyte dose-response curves, the authors observed two plateaus, which, by modeling of
the dependence of the optical signal on the degree of cluster formation, they could attribute to a low
analyte concentration regime where only particle singlets and doublets exists, and a higher analyte
concentration regime where particle multiplets are also formed [234].
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realized a biosensor based on measuring the magnetorotation of magnetic particles that assemble into 
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laser or LED light source from above, and the particle cluster is observed from below either by an 
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by an applied RMF, and the frequency of the RMF is chosen well above the critical frequency of the 
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direction of the applied RMF decreases with increasing RMF frequency [233,236]. By performing a 
FFT of the optical signal, the net rotation rate of the particle cluster is determined, and changes in the 
particle cluster assembly (e.g., cluster expansion or volume increase) or the local fluid viscosity alter 
the net rotation rate of the particle cluster (see Figure 12b) [235]. By employing this measurement 
principle and magnetic particles (2.8 µm diameter by Invitrogen, Waltham, MA, USA) functionalized 
by E. coli antibodies, Kinnunen et al. performed E. coli bacteria growth studies, including 
determination of the minimum inhibitory concentration of the two antibiotics streptomycin and 
gentamicin [235]. Here, bacteria growth on the particle cluster caused an increase of the cluster 
volume, thus leading to an increase of its rotational period [235]. In the following, the group 
expanded their analysis to the blood coagulation factor thrombin by observing clusters of magnetic 
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Detection of Bead Assembly Magnetorotation
Instead of adjusting the experimental parameters to a regime where mainly formation of particle
doublets occurs, another approach is to analyze larger particle clusters. To that end, Kinnunen et al.
realized a biosensor based on measuring the magnetorotation of magnetic particles that assemble
into a cluster at the bottom of a hanging droplet (see Figure 12a) [235]. The droplet is illuminated
by a laser or LED light source from above, and the particle cluster is observed from below either by
an inverted microscope or by a photodetector [235]. Here, the droplet also serves as a le s to magnify
the sh dow image of the pa ticle clust r 100-fold [235]. The particle cluster is rotated in the image
plane by an applied RMF, and the fr que cy of the RMF is chosen well above the critical frequency of
the particle cluster [235]. The critical frequency is defined as the maximum rotation frequency at which
a magnetic particle (or particle cluster) can still follow the applied RMF synchronously (i.e., equality
of magnetic and hydrodynamic drag torque) [233,236]. Above this critical frequency, the particle (or
particle cluster) experiences an asynchronous motion, and the superimposed net rotation rate in the
direction of the applied RMF decreases with increasing RMF frequency [233,236]. By performing a FFT
of the optical signal, the net rotation rate of the particle cluster is determined, and changes in the
particle cluster assembly (e.g., cluster expansion or volume increase) or the local fluid viscosity alter
the net rotation rate of the particle clus e (see Figure 12b) [235]. By employing this measurement
Sensors 2016, 16, 828 21 of 49
principle and magnetic particles (2.8 µm diameter by Invitrogen, Waltham, MA, USA) functionalized
by E. coli antibodies, Kinnunen et al. performed E. coli bacteria growth studies, including determination
of the minimum inhibitory concentration of the two antibiotics streptomycin and gentamicin [235].
Here, bacteria growth on the particle cluster caused an increase of the cluster volume, thus leading
to an increase of its rotational period [235]. In the following, the group expanded their analysis to
the blood coagulation factor thrombin by observing clusters of magnetic particles (1 µm diameter by
Invitrogen, Waltham, MA, USA) functionalized by two different thrombin-specificaptamers [237]. The
main effect of thrombin target protein binding to the particles was an expansion of the gaps between
the particles, thus leading to larger cluster volumes and increased rotational periods [237]. The authors
also determined the dependence of the fractal dimension of the particle clusters on the thrombin
concentration by optical microscopy, which showed a good agreement to the magnetorotation period
analysis [237]. In buffer, the authors demonstrated a thrombin detection limit as low as 80 fM [237],
which, however, increases to about 7.5 nM in serum (see SI of [237]), which the authors mainly attribute
to the low specificity of the aptamer receptors [237]. Lately, the group also presented a prototype
version of their measurement principle, which no longer requires a microscope or hanging droplets,
but is realized on three stacked 384-well plates and enables 48-plex detection [238]. The middle plate
contains the sample and the particle cluster, while the top and bottom plate incorporate the optics
(LED light sources and photodiode detectors, respectively) [238]. The authors demonstrated detection
of E. coli bacteria (LoD 5000 cfu/mL) within a total analysis time of about 90 min and also determined
the minimum inhibitory concentration of the antibiotic gentamicin [238].
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magnetic field (2nd harmonic spectrum) [239]. As larger magnetic clusters are formed by  
analyte-induced binding, the hydrodynamic drag of the clusters increases, resulting in an altered 
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Optomagnetic Detection Incorporating Blu-ray Optics
A highly integrat d opt magnetic device for measur ng the response of magnetic parti le clusters
to an applied magnetic field that makes use of Blu-ray optical components and a microfluidic disk has
lately been introduced by Donolato et al. [239]. Figure 13 displays a sketch of the most recent version
of the employed setup, where the magnetic particle labels within the detection chamber are excited
by a linear AC magnetic field generated by electro agnets placed above and below the microfluidic
disk [240]. The dynamic respon e of the particle l bels t the AC magnetic fi ld is etermined
optically by transmission measurements of light emitted from a Blu-Ray laser diode an picked up
by a photodetector [240]. The measurement signal is given by the 2nd harmonic of the photodetector
signal, which is usually recorded as a function of the frequency of the applied AC magnetic field
(2nd harmonic spectrum) [239]. As larger magnetic clusters are formed by analyte-induced binding,
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the hydrodynamic drag of the clusters increases, resulting in an altered magnitude and frequency
of the peak in the 2nd harmonic spectrum [239]. As an initial proof-of-concept of the method,
Donolato et al. demonstrated DNA-based detection of E. coli bacteria following isothermal rolling
circle amplification (RCA), employing magnetic particles (100 nm diameter by Micromod, Rostock,
Germany) functionalized by oligonucleotide detection probes that bind to the DNA coils produced
by the RCA, and demonstrated a detection limit of about 10 pM of DNA coils in buffer solution [239].
In the following, the group evaluated different sensing geometries, and found out that a configuration
with perpendicular alignment of the AC magnetic field to the optical axis and parallel alignment of the
linear polarization direction of the incident light to the AC magnetic field gives the largest signal, which,
in addition to the already previously introduced E. coli bacteria detection via RCA products [239],
they demonstrated for the detection of biotinylated BSA model analyte by streptavidin-functionalized
magnetic particle labels (obtained detection limit in buffer ~100 pM) [241]. By adding an incubation
step in a sufficiently strong static magnetic field to accelerate particle clustering via bound analyte
molecules prior to data acquisition (see permanent magnets in Figure 13) and digesting the DNA
coil RCA products into monomers, the group demonstrated simultaneous detection of three different
bacteria causing urinary tract infection (E. coli, Proteus mirabilis and Pseudomonas aeruginosa) [242].
In addition, they showed identification of E. coli bacteria from 28 urine samples with 100% specificity
compared to standard clinical laboratory plate culture data [242]. The group also adapted their method
to a competitive assay format for the detection of the small molecule adenosine triphosphate (ATP),
showing a detection limit of about of 74 µM in buffer and a dynamic range of ~0.1–10 mM, which
conforms well to the clinically relevant ATP concentration range [224]. Next, the group showed direct
detection of Salmonella bacteria by a competitive assay incorporating two types of magnetic particles,
i.e., large capture particles (5 µm diameter by Micromod, Rostock, Germany) and small detection
particles (100 nm diameter by Micromod, Rostock, Germany) [243]. Following a sedimentation step
of the large capture particles, the concentration of the remaining detection particles is measured,
which due to the competitive assay format scales with the concentration of bacteria, resulting in
a detection limit of about 80,000 cfu/mL in buffer [243]. The latest application demonstrated by the
group concerns quantification of the dengue fever protein biomarker NS1 by magnetic particle labels
(170 nm diameter by Merck, Darmstadt, Germany) functionalized by two different monoclonal NS1
antibodies, resulting in a detection limit of 25 ng/mL (corresponds to ~500 pM at a NS1 molecular
weight of 46–55 kDa [244]) measured directly in spiked serum samples [240].
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The easiest way to optically sense the formation of particle clusters in an applied magnetic field, 
is, of course, by naked-eye detection. This detection modality has been introduced by Leslie et al., 
who applied a rotating magnetic field (RMF) to magnetic particles dispersed in a microfluidic well to 
detect DNA via particle cluster formation, which is quantified by digital image analysis [245].  
Figure 14 shows a sketch of the group’s latest setup [246], which in addition to the RMF also 
incorporates agitation of the particles by a vortexer (‘dual-force’ [247]) to enhance the homogeneity 
of cluster formation across multiple neighboring wells (12 wells demonstrated), but also to speed up 
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Naked Eye Detection of Particle Clusters
The easiest way to optically sense the formation of particle clusters in an applied magnetic field,
is, of course, by naked-eye detection. This detection modality has been introduced by Leslie et al., who
applied a rotating magnetic field (RMF) to m gnetic particles dispersed in microfluidic well to detect
DNA via particle cluster formation, which is quantified by digital image an lysis [245]. Figure 14
shows a sketch of the group’s latest setup [246], which in addition to the RMF also incorporates
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agitation of the particles by a vortexer (‘dual-force’ [247]) to enhance the homogeneity of cluster
formation across multiple neighboring wells (12 wells demonstrated), but also to speed up the required
incubation time and to enhance the detection limit [247]. The images in Figure 14 show the distribution
of magnetic particles following the agitated incubation for a control without analyte DNA (´) and
a sample with analyte DNA (+), the presence of which induces agglomeration of particle labels visible
to the naked eye [246].
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different oligonucleotides complementary to the 5′ and 3′ end of the target sequence [245]. Later, still 
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Following introduction of the dual-force setup [247], the group systematically analyzed the 
influence of different target sequence parameters on the HIA efficiency of the target to 
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three base mismatches [246]. The latter analysis was further advanced for detecting single nucleotide 
polymorphism mutation of the KRAS gene from pancreatic and lung cancer cell lines by the dual-force 
setup, demonstrating efficient HIA discrimination of mutant and wild-type KRAS genes following 
polymerase chain reaction (PCR) amplification to a minimum number of 1012 copies [250]. 
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by performing sequence-specific DNA amplification reactions up-front. However, efficient CDA 
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In their initial work using RMF agitati n only, the authors demonstrated total DNA concentration
detection by aggregation of magnetic particles (8 µm diameter magnetic silica particles by Promega,
Madison, WI, USA) for direct white blood cell count from human whole blood samples [245].
This ‘chaotrope-driven aggregation’ (CDA, [245]) is caused by unspecific adsorption of DNA onto
particles with silica surface driven by NA dehydration, which is induced by the addition of chaotropic
salts [248]. Furthermore, the authors could also achieve detection of sp cific DNA sequences (synthetic
26-base target) by ‘hybridization induced aggregation’ (HIA, [245]) recognition of magnetic particles
(1 µm diameter Dynabeads by Invitrogen, Waltham, MA, USA) functionalized by two different
oligonucleotides complementary to the 51 and 31 end of the target sequence [245]. Later, still making use
of the RMF-only setup, the group extended their total DNA concentration CDA analysis to microbial
growth testi g (E. coli detection) as well as differentiation of CD4+ T-Cells, the latter achieved by
adding an immuno gn tic separation step up-front [249].
Following introduction of the dual-force setup [247], the group systematically analyzed
the influence of different target sequence parameters on the HIA efficiency of the target to
oligonucleotide-functionalized magnetic particles, also including differentiation of one, two and
three base mismatches [246]. The latter analysis was further advanced for detecting single nucleotide
polymo phism mutation of the KRAS gene from pancreatic and lung cancer cell l nes by the dual-force
setup, demonstrating efficient HIA discrimi ation of mutant and wild-type KRAS genes following
polymerase chain reaction (PCR) amplification to a minimum number of 1012 copies [250].
While the CDA approach is intrinsically non-specific, it can also be turned into a specific detection
by performing sequence-specific DNA amplification reactions up-front. However, efficient CDA
requires DN lengths of at least 10 kilo-base-pairs (kbp), while the products of amplification reactions
are usually m ch short r [251]. By introducing a ompetitive assay form t, where rising oncentrations
of the amplification product increasingly inhibit magnetic particle agglomeration that is induced by
addition of a fixed concentration of 48 kbp long λ-phage DNA, DuVall et al. demonstrated successful
detection of the food-borne pathogens E. coli and Salmonella as well as the Rift Valley fever virus by
CDA following loop-mediated isothermal amplification (LAMP) [251].
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An even simpler CDA analysis procedure called ‘pipette, aggregate and blot’ (PAB) was
introduced by Li et al. [252]. Here, the magnetic particles and the sample are sequentially picked
up by a pipette, and the mixture within the pipette tip is exposed to a static magnetic field to
induce DNA-mediated formation of aggregates [252]. Next, the fluid is dispensed onto a filter paper
(‘blotting’), on which the degree of particle aggregate formation is determined by digital photography
and image analysis, i.e., a process that can also be accomplished by any smart phone [252]. The authors
demonstrated detection of human genomic DNA from purified whole blood by the PAB technique and
showed that the achievable detection limit depends on the size of the employed magnetic particles
(800 ng/mL for 1 µm diameter by Invitrogen, Waltham, MA, USA, and 6.4 µg/mL for 8 µm diameter
magnetic silica particles by Promega, Madison, WI, USA) [252]. While this does not reach the detection
limit of 250 pg/mL demonstrated for genomic DNA detection by CDA analysis using the dual-force
setup [247], the PAB approach has an advantage with regard to its simplicity.
A very similar procedure was followed by Lin et al, who exposed mixtures of magnetic particles
(1 µm diameter by Invitrogen, Waltham, MA, USA) and the sample solution to multiple sequences of
aggregation (application of a static magnetic field) and re-suspension [253]. Following dispensing of
the mixture onto a filter paper, the degree of particle clustering is determined by digital image analysis
of the filter paper [253]. The authors demonstrated their method for the detection of the human
papilloma virus type 18 gene following rolling circle amplification (RCA), and could successfully
distinguish positive samples (genomic DNA isolated from HeLa cells) from negative control samples
(genomic DNA isolated from human hepatoma cells) [253].
With the exception of total DNA content determination by CDA ([247,252], the CDA part of
Reference [245] and the white blood cell analysis part of [249]), all naked-eye detection papers
presented above do not strictly fall into the category of one-step homogeneous detection, as they
do involve some sort of upfront sample preparation, i.e., immunomagnetic separation (CD4+ T-Cell
detection part of [249]), DNA amplification [250,251,253] or DNA purification ([246], HIA part of [245]).
A true one-step analysis procedure comprising analyte-mediated formation of particle clusters in an
applied magnetic field has lately been introduced by Chen et al. [254]. Figure 15 shows a schematic
representation of the measurement principle employed by the authors, which they designate as
‘immunomagnetic aggregation’ (IMA) [254]. Here, a static magnetic field is applied that attracts
the magnetic particles (immunomagnetic beads, IMB) to the side wall of the sample tube, and the
structure of the resulting agglomerate depends on the presence of target molecules in the solution [254].
The reason is the increased diameter and decreased net magnetization of an IMB-target complex
as compared to blank IMBs, which influences the balance between the attractive magnetic force
component tangential to the wall and the friction force, thus leading to an expanded arc-shaped
aggregation of IMB-target complexes along the tube wall as opposed to a compact stripe-shaped form
for blank IMBs (see top view representation in Figure 15) [254]. The authors compare their naked-eye
IMA detection results to gold lateral flow strip (GLFS) references [254]. In addition, by analysis of
digital images taken from the sample tubes, the authors extract an average grey scale value that
semi-quantitatively depends on the target molecule concentration and can be used to compare the
IMA data with dose-response curves obtained from enzyme-linked immunosorbent assay (ELISA)
based reference detection [254]. Employing magnetic beads (200 nm diameter Estapor particles by
Merck, Darmstadt, Germany) functionalized by polyclonal E. coli antibodies, the authors demonstrate
a detection limit of about 104 cfu/mL for the direct detection of E. coli bacteria in spiked river water
samples within 15 min, which is one order of magnitude more sensitive than reference GLFS detection,
and about ten times faster than reference ELISA detection [254]. Besides, the authors likewise confirm
correct IMA-based identification of E. coli contamination of non-spiked water samples obtained from
a livestock farm [254]. In addition to bacteria, the authors also show detection of the cancer biomarker
proteins alpha fetoprotein (AFP) and carcino-embryonic antigen (CEA) directly in spiked urine samples
using magnetic particles functionalized by pairs of respective monoclonal antibodies, and achieve
a detection limit of about 2.5 ng/mL for AFP and 2.0 ng/mL for CEA, both of which are well below
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the clinical cut-off values [254]. Finally, the authors successfully discriminate AFP and CRP positive
from negative patients by IMA-analysis using non-spiked clinical serum samples [254].Sensors 2016, 16, 828 25 of 48 
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3.2. Detection by Intrinsically Optically Anisotropic Magnetic Labels
An alternative to generating optical anisotropy by inducing clustering of intrinsically optically
isotropic particles (see Section 3.1) is to make use of magnetic particle labels that display an intrinsic
optical anisotropy. To that end, three main approaches have been followed. One possibility is to
make use of magneto-optical effects (i.e., the Faraday or the Cotton-Mouton effect) as source of
optical anisotr py, which usually result in changes of the polarization state of the incident light
as optical measurement signal (s e Section 3.2.1). Alternatively, optical anisot opy can be created
by hemi-spherical coating of initially optically isotropic spherical particles (see Section 3.2.2) or by
employing particle labels with shape anisotropy (e.g., rod-shaped particles, see Section 3.2.3). In the
latter two cases, the optical measurement signal usually comprises a change in the transmission or
scattering intensity of the particle labels.
3.2.1. Magneto-Optical Detection of Magnetic Particle Labels
When an external magnetic field is applied to a suspension of magnetic particles, their magnetic
moments align parallel to the applied field, and the suspension becomes birefringent and dichroic.
As the dichroism induced in magnetic particle suspensions is usually much smaller than the
birefringence [255], it is normally neglected in the analysis. Both, the Faraday effect (magnetic
circular birefringence, magnetic field applied parallel to the direction of light propagation, [256]) and
the Cott n-Mouton effect (magnetic linear birefr ngence; agnetic field applied perpendicular to the
direction of light propagation, [257]) have been exploited to magneto-optically characterize magnetic
particles. Regarding the measurement modes, linearly polarized light is incident onto the sample, and
the magnetic field amplitude either varies sinusoidal with time (AC susceptibility mode, [258]), or is
applied as a step function (magnetorelaxation (MRX) mode, [259]).
Magneto-optical methods ar sensitiv to changes in the Brownian rel xation tim of magnetic
particle suspensi ns, and, consequently, hav been applied to study hydrodynamic particle
diameter distributions [260] or medium viscosities [261]. A typical setup, as it is employed to
magneto-optically (Cotton-Mouton effect) measure the relaxation of the magnetization of a particle
ensemble after an externally applied uniaxial magnetizing field is turned off (MRX mode), is sketched
in Figure 16a [262]. It comprises a laser light source that is linearly polarized by a polarizer aligned
at ´45˝ relative to the orientation of the magnetic field, which is oriented perpendicular to the
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propagation direction of the light and is generated by a Helmholtz coil. In the center of the Helmholtz
coil, the sample containing the particle dispersion within a non-birefringent cuvette is positioned.
When the magnetic moments of the particles are aligned by the applied magnetic field, the suspension
becomes birefringent, and the transmitted light gets elliptically polarized [263]. The physical origin of
the optical anisotropy can be related to crystalline or shape anisotropy of the particle cores, but for
the commonly applied iron-oxide NPs mostly arises from surface magnetic anisotropy [263]. After
passing the quarter wave plate, which is aligned with its slow axis parallel to the polarizer, the light is
again linearly polarized, but shifted in polarization by a birefringence-proportional phase lag [263].
As a result, some light can pass the analyzer, which is oriented at +45˝ relative to the magnetic field
(i.e., perpendicular to the polarizer), and, consequently, blocks the incident light if no birefringence is
induced in the sample (i.e., the particles are randomly oriented) [263]. The transmitted light is measured
by a photodiode detector, which in this configuration is proportional to the induced birefringence [262].
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Figure 16. (a) Sketch of a typical setup for magneto-optically (Cotton-Mouton effect) measuring 
changes in the relaxation time of magnetic particles. Graph reproduced with permission from [262]. 
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of the particles relaxes, the measured intensity falls off exponentially (green curve), but with a larger 
time constant if analyte molecules have bound to the particle surface (red curve). 
Figure 16b schematically shows the time dependence of the measured light intensity for a setup 
as the one described in Figure 16a. When the magnetic field is turned on, birefringence in the sample 
is induced, and the measured intensity reaches a stationary value I0 [264]. When the magnetizing field 
is turned off, the magnetic particles transit back to a random state. For particles that predominantly 
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proportional to the cube of their hydrodynamic diameter [262]. Since analyte molecules bound to the 
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the particles relaxes, the measured intensity falls off exponentially (green curve), but with a larger time
constant if analyte molecules have bound to the particle surfac (r d curve).
Figure 16b schematically shows the time dependence of the measured light intensity for a setup
as the one described in Figure 16a. When the magnetic field is turned on, birefringe ce n the sample
is induced, and the measured intensity reaches a stationary value I0 [264]. When the magnetizing field
is turned off, the magnetic particles transit back to a random state. For particles that predominantly
relax their net magnetization via Brownian rotational motion, the measured intensity exponentially
decays to zero with a time constant given by th Brownian relaxation time of the pa ticles, which is
proportional to the cube of their hydrodynamic diameter [262]. Since analyte molecules bound to
the particle surfaces increase their hydrodynamic radii, the measured intensity of analyte-carrying
particles (red curve) decays slower than for plain reference particles (green curve). By fitting the
measured in ensity by exponential d cay curves and integrating a ross the particle diameter [262],
the hydrodynamic diameter distribution of the particle ensemble can be deduced. Alternatively, the
intensity curve can also be fitted by a stretched exponential, where the size distribution of the particles
is described by a polydispersity index [264].
Owing t their high s nsiti ity to cha ges in the hydrodynamic shell t ickness, m gneto-optical
methods are well suited as homogeneous particle-based biosensors that can be applied also to studies
in dense and highly scattering media, which makes them advantageous to other techniques such
as dynamic light scattering (DLS). For example, Köber et al. demonstrated in-situ evaluation of
the hydrodynamic diameter distribution of magnetite NPs with three different surface coatings
(plain PMAO polymer, galactose and PEG) directly within the agarose carrier matrix used for gel
electrophoresis, and the obtained diameters have been shown to be independent on fluctuations of the
NP concentration along the gel [262].
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Stepwise increases in the mean hydrodynamic diameters of carboxylated magnetite NPs on the
covalent attachment of avidin, followed by functionalization with biotinylated immunoglobulin G
(IgG) antibodies and binding of IgG antigen has been demonstrated by Ku et al., and they showed
that the measured NP diameter increases are well in line with the expected hydrodynamic sizes of the
respective molecules [265].
Lartigue et al. carried out magneto-optical characterization of the formation of protein coronas
around maghemite NPs for three different NP coatings (carboxylic moieties, glucose and citrate)
by incubating them with different concentrations of both BSA and whole blood rat plasma [266].
They showed that the formation of the protein corona depends both, on the NP surface coating and the
plasma concentration [266]. Here, the glucose coating efficiently prevents further adhesion of plasma
proteins, while citrate-coated NPs and NPs with carboxylic moieties first undergo cluster formation
at low plasma concentrations (10%–20%), while larger plasma concentrations lead to single particle
stabilization with a mean protein corona thickness of 8.8 nm [266].
The largest signal in magneto-optical biosensing can be achieved when the analyte molecule
contains multiple binding sites and, consequently, induces cross-linking of the particles. This is
demonstrated by Glöckl et al., who carried out a direct comparison of multicore maghemite NPs
functionalized by monoclonal antibodies against PSA and by polyclonal antibodies against IgG [267].
They observed a significant increase in the relaxation time of the NPs only for IgG analyte, which
they explained by the analyte-induced formation of NP clusters functionalized by polyclonal
antibodies [267]. For the detection of carcinoembryonic antigen (CEA), however, the group obtained
cluster formation both for NPs (same type as employed in [267]) functionalized by monoclonal and
polyclonal antibodies, and a detection limit for CEA in buffer in the lower nanomolar regime could be
demonstrated [268]. Employing magnetic NPs functionalized by polyclonal antibodies (same type
as employed in [267]), the group also investigated the detection of immunoglobulin M (IgM), IgG,
eotaxin, CEA and insulin [269] as well as insulin-like growth factor 1 (IGF-1) [270], and they could
demonstrate a detection limit in the lower nanomolar regime for CEA [269] and IGF-1 [270] and in the
picomolar regime for IgG [269]. Furthermore, on the basis of linear chain formation model, the group
derived a distribution function of particle clusters, and by fitting the measured intensity curves to this
model, they could determine the time evolution of the relative number of monomers, dimers, trimers,
etc. [269]. In addition, from the analysis of the time dependence of the measured relaxation curves
for different analyte concentrations, the group determined the kinetic parameters for the binding of
eotaxin [269,271], CEA [268,269] and IGF-1 [270] to NPs functionalized by respective antibodies, and
compared the results to surface plasmon resonance (SPR) data [269,271].
Similarly, the binding of the lectin concanavalin A (ConA) to carbohydrate-functionalized
magnetite NPs was analyzed by Köber et al. [272]. They applied the Hill equation to study the
analyte-driven formation of clusters, and directly determined the association and dissociation rate
constants by homogeneous magneto-optical measurements by first adding varying concentrations
(nanomolar range) of ConA analyte (association), and later adding excess amounts of free
carbohydrates (50 millimolar of mannose or glucose) that practically completely dissociates the
analyte from the NPs [272]. The demonstrated detection limit for ConA was in the lower nanomolar
range [272].
3.2.2. Hemispherically Coated Spherical Particle Labels
Particles with asymmetric properties are commonly designated as ‘Janus’ particles in reference to
the two-faced Roman God Janus, a term that has been promoted by P.G. de Gennes in his Nobel Prize
address in 1991 [273]. A number of comprehensive reviews have been published within the past decade
that detail the different variants, fabrication strategies and applications of Janus particles [274–279].
Specifically relevant to this review article are magnetic Janus particles for in vitro diagnostic
applications as they have been introduced by the term magnetically modulated optical nanoprobe
(MagMOON) by the Kopelman group. In its initial realization, Anker et al. employed magnetic
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microspheres (particles by Spherotech, Lake Forest, IL, USA) that have been coated on one hemisphere
by a sputter-deposited gold layer that blocks excitation and detection of fluorophores bound to the
non-coated streptavidin-functionalized hemisphere [218]. Consequently, by controlling the alignment
of the MagMOONs in the solution by an applied magnetic field, the observed fluorescence intensity can
be modulated (see Figure 17) [218]. In a demonstration experiment, the authors mixed the MagMOONs
with two different biotinylated fluorophores and showed concentration-dependent detection of the
fluorophores bound to the MagMOON particles at their respective wavelengths above the large
background of non-bound fluorophores by magnetically modulating the particle orientation in the
solution [218]. Similarly to the particle chains described in Section 3.1.1 [219], the MagMOONs can,
therefore, be employed as substrates with magnetically modulated fluorescence contrast to directly
carry out sandwich immunoassays in the homogeneous sample solution phase without requiring
washing [218]. The group also demonstrated detection of single E. coli bacteria by microscopically
observing the magnetorotation of individual MagMOONs (E. coli antibody functionalized magnetic
particles with a diameter of 2 µm by Spherotech, Lake Forest, IL, USA, which are hemispherically
coated by a 50 nm thick aluminum layer) [280]. The authors applied a rotating magnetic field (RMF) at
a frequency well above the critical frequency of the MagMOON [280], i.e., the limiting frequency at
which a magnetic particle can still follow the applied RMF synchronously [233,236]. Above this critical
frequency, the particle experiences an asynchronous motion, and the superimposed net rotation rate in
the direction of the applied RMF decreases with increasing RMF frequency [233,236]. The authors could
show that due to the increasing hydrodynamic drag, the measured net rotation rate of the MagMOONs
sensitively depends on the number of bound E. coli bacteria, thus providing a tool for homogenous
and label-free quantification of bacteria concentrations [280]. Ensemble measurements of MagMOONs,
however, are hampered by the rather inhomogeneous magnetization of most available magnetic
microspheres [281]. This problem has been addressed by hemispherically coating homogeneous size
standard polystyrene particles (diameters of 1, 2, 10 and 100 µm by Polysciences Inc., Warrington, PA,
USA) by a nickel layer, thereby reducing the magnetic response variability of the MagMOONs by up to
almost one order of magnitude compared to previous results using coated magnetic microspheres [281].
An increase in the throughput of biosensing by observing the magnetorotation of MagMOONs can
be accomplished by a droplet-based microfluidic analysis platform, which Sinn et al. introduced
and demonstrated for E. coli bacteria growth studies, including fast determination of the minimum
inhibitory concentration of the antibiotic gentamicin [282,283].
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Figure 17. Sketch of modulated fluorescence by magnetic particles with a hemispherical metal
coating (dark-shaded area). The coating prevents excitation/detection of fluorophores at the particle
surface when the particle is rotated with the coated side towards the excitation source/observation
optics by an applied magne ic field, resulting in magnetically controllable modulation of the
observed fluorescence. Modified graph reprinted with permission from [218]. Copyright 2003, AIP
Publishing LLC.
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Furthermore, the group also demonstrated a stand-alone prototype instrument that no longer
requires an optical microscope setup, but measures the magnetorotation of individual MagMOONs by
a compact optical setup consisting of a laser diode source and a photodiode detector [284]. Combining
such compact optics and high throughput droplet microfluidics, MagMOON magnetorotation as well
as the related methodology of ‘label acquired magnetorotation’ [285,286] have the potential to also
find applications beyond research tools.
3.2.3. Magnetic Labels with Optical Shape Anisotropy
In this section, we review methods that make use of an intrinsic optical anisotropy of rod-shaped
particle labels (nanorods) to optically monitor their orientation in the sample solution. This is enabled
by differences of the optical polarizability of nanorods along their principal axes in linearly polarized
light [287]. In the following, we discuss a biosensing principle based on this effect as it has been
introduced by Schrittwieser et al. [288,289]. Two distinct types of magnetic nanorods are presented,
i.e., nickel (Ni) nanorods [290] and noble metal shell coated cobalt (Co) nanorods [288,289,291].
The measurement method can be applied for detection [291] as well as analysis [290,291] of proteins
in solution.
Measurement Principle
Nanorods consisting of a ferromagnetic core and an antibody-functionalized noble metal shell are
optimal probes for this method [289,291], which is based on detecting an increase of the hydrodynamic
nanoprobe volume upon binding of target molecules (see sketch of the method in Figure 18) [288–291].
The nanoprobes immersed in the sample solution are excited by an external rotating magnetic field
(RMF), which they follow coherently due to their permanent magnetic moment that is fixed along the
nanorod axis as a consequence of the magnetic shape anisotropy [292,293].
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Figure 18. Sketch of the biosensing principle making use of magnetic particle labels with intrinsic
optical shape anisotropy: (a) Rod-shaped nanoprobe comprising a magnetic core and a noble metal
shell with antibodies on the particle surface for specific binding of target proteins; (b) The ferromagnetic
nanorod follows the applied rotating magnetic field (RMF) with a phase lag α due to the drag
torque experienced in the sample solution, which depends on the hydrodynamic nanoprobe volume;
(c) Binding of target proteins increases the hydrodynamic drag and, consequently, the phase lag α;
(d) The transmission of linearly polarized light is detected. Its in ensity directly relate to the actual
orienta on of the nanoprobe wi h respect o the polarization dir ction (angle α). Comparison of the
optical signal with the omentary orientation of the RMF allows deduction of the angle α. Reprinted
with permission from [291]. Copyright 2016, American Chemical Society.
Sensors 2016, 16, 828 30 of 49
The rotational behavior depends on the hydrodynamic nanoprobe drag, which causes the
nanoprobe orientation to lag behind the momentary direction of the RMF by a specific phase lag
α (see Figure 18). Binding of target proteins increases the hydrodynamic nanoprobe volume and drag,
thus leading to an increase of the phase lag α. This change in the phase lag represents the measurement
signal for this method. To detect these phase lag changes, the anisotropic absorption and scattering
properties of the nanorods in linearly polarized light are exploited. Specifically, the detected optical
signal intensity depends on the actual orientation of the nanoprobes with respect to the direction
of polarization of the incoming light [287]. For measurements performed in transmission geometry,
nanoprobes aligned perpendicularly to the polarization show a maximum of transmission, and vice
versa. Therefore, it is possible to deduce the momentary orientation of the nanoprobes by analyzing
the optical signal. Comparison of the actual magnetic field orientation with the momentary nanoprobe
orientation allows deducing the phase lag α, i.e., the measurement signal of interest. The experimental
setup for biosensing measurements by this method consists of two pairs of Helmholtz coils aligned
perpendicularly to each other, which are fed by two sinusoidal currents that are phase-shifted by 90˝.
By adjusting the current amplitudes, a uniform rotating magnetic field is generated, with the sample
placed in the center of the coil pair arrangement. The optical part of the setup simply consists of a laser
diode, a polarizer, and a photodetector arranged in transmission geometry. A Lock-in amplifier is
applied to compare the magnetic signal (specifically: voltage drop across a shunt resistor) with the
optical signal. Details on the measurement setup can be found in literature [289,294,295], Due to the
symmetry of the applied cylindrical nanorods, the optical signal is frequency doubled with respect to
the magnetic excitation. Actual measurements can be carried out under variation of the frequency of
the externally applied RMF (phase lag spectra), or at a single frequency for rapid analysis.
Ni Nanorod Protein Binding Results
Nickel nanorods were synthesized by electrochemical deposition into porous alumina
templates [292]. In a two-step anodization process [296], aluminum foils are anodized in sulfuric
acid, which results in the formation of a porous alumina surface layer. The two-step anodization
process is necessary to obtain ordered homogeneous porous surface layers of small thickness [296].
Next, the non-conductive oxide layer at the pore bottom was thinned by voltage limited anodization
and diameter fluctuations of the pores were reduced by immersion of the foils in phosphoric acid [287].
The so created pores were filled with Ni in a Watts bath by pulsed electrodeposition [297]. Negative
and positive voltage pulses were applied periodically to yield homogeneous nanorod growth (see [292]
for details). Finally, the nanorod-enclosing aluminum oxide was dissolved in sodium hydroxide with
the addition of polyvinylpyrrolidone (PVP) with a molecular weight of 3500 Da as surfactant for
nanorod dispersion stabilization. Washing with water and re-dispersion of the nanorods was done by
repetitive precipitation in the centrifuge and sonication.
Figure 19a shows a transmission electron microscopy (TEM) image of the final single-particle
dispersed nanorod solution. The mean values and standard deviations of the Ni nanorods lengths
and diameters were determined by TEM image analysis, and the mean particle magnetic moment was
obtained by vibrating sample magnetometry (VSM) measurements [290].
Protein binding to the surface of the Ni nanorods was examined by recording and comparing
phase lag spectra of nanorod solutions with and without added protein. BSA was chosen as
model protein that binds nonspecifically to the nanorod surface [298]. To quantify the protein shell
thickness, a recently developed theoretical model [299] was applied to carry out model fits of the
measurement results.
Ni nanorods were employed together with a BSA concentration sufficient for at least five times
full protein coverage of the nanorod surface [290]. Note that however for similar coatings no more
than a monolayer of proteins can be adsorbed [300]. Figure 19b shows the measured phase lag spectra
of Ni nanorods at an external magnetic field strength of 1 mT [290]. Here, the dots represent measured
values, while the lines correspond to the results of the fitting procedure. Absolute phase lags of plain
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nanorods without bound protein (black) and nanorods with bound BSA protein (grey) are plotted
against the left y-axis, while the phase lag difference (blue) between the two NP states is plotted against
the right y-axis. At each state, the nanorods show a specific hydrodynamic shell thickness on top of
the bare metal nanorod surface, which for plain nanorods comprises the PVP surfactant layer and
the stagnant surface layer, while for nanorods with bound BSA, the thickness of the protein shell is
added to the total shell thickness. By fitting the measured phase lag spectra at both nanorod states by
the empirical equations derived from the respective theoretical model [299], the authors determined
an added protein shell thickness of about 22 nm [290].
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Figure 19. Ni nanorods and protein adhesion results: (a) TEM image of Ni nanorods. The scale bar
corresponds to 200 nm. The mean nanorod length is 182 ˘ 29 nm and the mean diameter 26 ˘ 3 nm.
Reprinted with permission from Reference [290]. Copyright 2014, John Wiley and Sons; (b) Phase lag α
spectra in dependence of the external magnetic field frequency f of Ni nanorods under addition of BSA
protein and of plain nanorods at an applied RMF strength of 1 mT (left axis) and corresponding relative
phase difference ∆α (right axis). Measured values (dots) are compared to the calculated model fits
(lines). The relative phase difference ∆α (blue) reaches a maximum value of about 22˝ at a frequency f
of 330 Hz. Modified graph reprinted with permission from [290]. Copyright 2014, John Wiley and Sons.
Noble Metal Coated Co Nanorod Protein Binding Results
The here presented Co nanorods possess a small diameter of ~5 nm, which means that surface
oxidation easily affects the entire volume. Thus, a precondition of applying Co nanorods for the
presented measurement method is the protection of the magnetic core against degradation. This was
achieved by a noble metal shell synthesized on top of the magnetic Co core. In the first main step, bare
Co nanorods were synthesized, which were covered in the second main step by a noble metal shell
of platinum (Pt) and gold (Au) via an interlayer of tin (Sn) (Co@SnPtAu nanorods). Both synthesis
steps are described in detail in literature (see [293,301]). In brief, bare Co nanorods were fabricated by
decomposing a cobalt coordination precursor in the presence of different ligands in anisole solution
under a hydrogen atmosphere at elevated temperature. In a next step, a Sn containing layer was grown
on top of the nanorod surface to reduce the interface energy between the Co core and the following
noble metal shell compounds. The first noble metal shell coating was done with Pt by reacting
a Pt precursor with the nanorod surface when immersed in toluene under hydrogen atmosphere,
which was then followed by a Au coating process under similar conditions, finally resulting in
Co@SnPtAu nanorods.
Co core noble metal shell nanorods that have been prepared as outlined above are stable against
oxidation and degradation of the magnetic core. Figure 20a shows a TEM image of a nanorod
batch with resulting mean particle lengths of 75 ˘ 6 nm and diameters of about 9.0 ˘ 4.5 nm [301].
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The polycrystalline nature of the nanorod shell is illustrated by the high resolution transmission
electron microscopy (HRTEM) image in Figure 20b. An elemental map of such a nanorod obtained
by scanning transmission electron microscopy energy-dispersive X-ray spectroscopy (STEM-EDX)
is shown in the Figure 20c–f. Here, the different metals are represented by different colors. It can
be seen that the growth of the noble metal shell materials takes place on different sections on the
nanorod surface. Both shell metals together form a continuous layer that protects the magnetic Co core
from oxidation, which was also shown by VSM measurements before and after exposure to air and
water [301].
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Figure 20. (a) TEM image of a Co core noble metal shell nanorod sample; (b) HRTEM image of a single
nanorod, indicating a polycrystalline noble metal shell; (c)–(f) STEM- EDX elemental maps of a single
nanorod to illustrate the location of the different shell elements (Co: green, Sn: blue, Au: red and
Pt: yellow). The scale bar for the STEM-EDX maps is 20 nm. Reprinted with permission from [301].
Copyright 2015, American Chemical Society.
The Co@SnPtAu nanorods are synthesized in organic solvents, so they have to be transferred to
aqueous solution to be applicable for any kind of biological measurement. To that end, the nanorods
were coated by an amphiphilic polymer consisting of a hydrophilic backbone and hydrophobic
side chains [302]. Stabilization of the NPs in water was achieved by charged carboxy groups of
the hydrophilic polymer backbone on the nanorod surface [291]. The advantage of these nanorods
compared to the Ni nanorods is the presence of the carboxy groups, which can be employed for
further surface modifications. This was accomplished by linking antibodies to the nanorods to target
a specific protein in a sample solution (contrary to the unspecific adhesion of BSA to the Ni nanorods as
described above). The analyte protein to be detected was the soluble domain of the human epidermal
growth factor receptor 2 (sHER2) and the antibody protein immobilized onto the nanorods was the
monoclonal IgG antibody trastuzumab. Both proteins are clinically applied for the detection and the
treatment of breast cancer [303].
Figure 21a shows the phase lag α spectra recorded at an external magnetic field strength of 5 mT
in buffer solution for nanorods without antibody functionalization (nanoreagent—black markers),
nanorods including the antibody shell (nanoprobe—red markers) and for nanoprobes fully coated
by the target protein (blue markers) [291]. Fitting of the experimental data (solid lines in the figure)
by the respective theoretical model [299] resulted in hydrodynamic shell thicknesses of 15 ˘ 9.5 nm
for the antibody shell and of 25 ˘ 13 nm for the antibody shell including bound target protein (both
measured on top of the nanoreagents). These values are in good agreement with respective protein
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sizes reported in the literature [291,304,305]. Here, the target protein sHER2 was added in saturation
(200 nM) to ensure full nanoprobe coverage [291]. Addition of BSA protein to the nanoprobes at an
even higher concentration (15 µM) did not result in a detectable change in phase lag (green markers),
thus demonstrating specific binding of the sHER2 target protein.
To detect the concentration of the target protein in solution, it is sufficient to measure the phase lag
difference ∆α of the nanoprobes to reference nanoprobes without added sHER2 at a single frequency.
To that end, a separate experimental setup was chosen to generate a higher magnetic field strength
of 10 mT at a fixed rotational frequency of 1000 Hz [291,295]. The respective sHER2 assay results are
shown in Figure 21b [291]. The sensitivity of the assay was determined by fitting the data by a logistic
function [152], which results in a limit of detection of 440 pM [291].
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Figure 21. Measured phase lag spectra and assay results for the detection of the sHER2 target protein: 
(a) Phase lag α in dependence of the frequency f of the applied external magnetic field of 5 mT strength. 
Plain nanorods without antibody functionalization (black), trastuzumab antibody functionalized 
nanoprobes (red), and nanoprobes with fully assembled target protein shell (blue) are compared. Here, 
the markers correspond to measured data points, while the lines originate from the fitting procedure. 
BSA protein is added to the nanoprobes to ensure the absence of unspecific binding (green markers);  
(b) Assay results for the sHER2 protein in spiked buffer samples. The markers denote measured phase 
lag differences, while the line represents a logistic fit function applied for determining the assay 
sensitivity. The external rotating magnetic field was applied at an amplitude of 10 mT at a frequency 
of 1000 Hz. Reprinted with permission from [291]. Copyright 2016, American Chemical Society. 
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which are important factors for point-of-care testing applications that are becoming more and more 
relevant in the fields of medicine, food control, agriculture or veterinary medicine. Due to their 
manipulability by applied magnetic fields, employing magnetic particles as labels to homogeneous 
biosensing offers further advantages with regard to total analysis time and signal-to-noise ratio. While 
some measurement techniques are already technically advanced, future challenges with regard to PoC 
applications usually involve the design of inexpensive and portable measurement devices as well as 
the fabrication of low-cost particle labels applicable for long-term storage. Another challenge is to 
establish multiplex detection of several biomarkers within the same sample solution. Finally, full-scale 
clinical trials will be required to prove the advantages of homogeneous biosensor principles based on 
magnetic particle labels over state of the art methods. Solving these future requirements will also 
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Figure 21. Measured phase lag spectra and assay results for the detection of the sHER2 target protein:
(a) Phase lag α in dependence of the frequency f of the applied external magnetic field of 5 mT strength.
Plain nanorods without antibody functionalization (black), trastuzumab antibody functionalized
nanoprobes (red), and nanoprobes with fully assembled target protein shell (blue) are compared. Here,
the markers correspond to measured data points, while the lines originate from the fitting procedure.
BSA protein is added to the nanoprobes to ensure the absence of unspecific binding (green markers);
(b) Assay results for the sHER2 protein in spiked buffer samples. The markers denote measured
phase lag differences, while the line represents a logistic fit function applied for determining the assay
sensitivity. The external rotating magnetic field was applied at an amplitude of 10 mT at a frequency of
1000 Hz. Reprinted with permission from [291]. Copyright 2016, American Chemical Society.
4. Conclusions
In this review, we have presented sensor principles based on magnetic actuation of magnetic
particle labels for in vitro homogeneous biosensing applications. Here, we discriminated between
sensing concepts applying magnetic detection methods and sensors relying on optical detection.
The underlying measurement principles of the different sensor concepts were presented and discussed.
Moreover, relevant application areas and reported biosensing results were reviewed. The presented
methods cover all areas of in vitro biosensing, including detection of small molecules like hormones,
nucleic acids, proteins and whole cells or bacteria.
Homogeneous detection methods are gaining rising attention due to their rapidity and simplicity,
which are important factors for point-of-care testing applications that are becoming more and more
relevant in the fields of medicine, food control, agriculture or veterinary medicine. Due to their
manipulability by applied magnetic fields, employing magnetic particles as labels to homogeneous
biosensing offers further advantages with regard to total analysis time and signal-to-noise ratio. While
some measurement techniques are already technically advanced, future challenges with regard to PoC
applications usually involve the design of inexpensive and portable measurement devices as well as
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the fabrication of low-cost particle labels applicable for long-term storage. Another challenge is to
establish multiplex detection of several biomarkers within the same sample solution. Finally, full-scale
clinical trials will be required to prove the advantages of homogeneous biosensor principles based
on magnetic particle labels over state of the art methods. Solving these future requirements will also
trigger improvements in particle label synthesis and in particle bio-functionalization techniques.
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DLS Dynamic light scattering
E. coli Escherichia coli
ELISA Enzyme-linked immunosorbent assay
FFT Fast Fourier transformation
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H-FABP heart-type fatty acid binding protein
HIA Hybridization induced aggregation
HRTEM High resolution tunneling electron microscopy






LAMP Loop-mediated isothermal amplification
LoD Limit of detection
MARIA Magnetic relaxation immunoassay
MPI Magnetic particle imaging
MRI Magnetic resonance imaging
MRSw Magnetic relaxation switch
MRX Magnetorelaxation
NMR Nuclear magnetic resonance
NP Nanoparticle
PAB pipette, aggregate and blot
PCR: Polymerase chain reaction
PoC Point of care
PSA Prostate specific antigen
PVP Polyvinylpyrrolidone
RCA Rolling circle amplification
RMF Rotating magnetic field
sHER2 soluble domain of the human epidermal growth factor receptor 2
SPR Surface plasmon resonance
SQUID Superconducting quantum interference device
STEM-EDX Scanning transmission electron microscopy energy-dispersive X-ray spectroscopy
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VSM Vibrating sample magnetometry
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92. Mihajlović, G.; Xiong, P.; von Molnár, S.; Ohtani, K.; Ohno, H.; Field, M.; Sullivan, G.J. Detection of single
magnetic bead for biological applications using an InAs quantum-well micro-Hall sensor. Appl. Phys. Lett.
2005, 87, 112502. [CrossRef]
93. Baselt, D.R.; Lee, G.U.; Natesan, M.; Metzger, S.W.; Sheehan, P.E.; Colton, R.J. A biosensor based on
magnetoresistance technology. Biosens. Bioelectron. 1998, 13, 731–739. [CrossRef]
94. Weddemann, A.; Albon, C.; Auge, A.; Wittbracht, F.; Hedwig, P.; Akemeier, D.; Rott, K.; Meissner, D.;
Jutzi, P.; Hütten, A. How to design magneto-based total analysis systems for biomedical applications.
Biosens. Bioelectron. 2010, 26, 1152–1163. [CrossRef] [PubMed]
95. Wang, S.X.; Bae, S.-Y.; Li, G.; Sun, S.; White, R.L.; Kemp, J.T.; Webb, C.D. Towards a magnetic microarray for
sensitive diagnostics. J. Magn. Magn. Mater. 2005, 293, 731–736. [CrossRef]
96. Miller, M.M.; Sheehan, P.E.; Edelstein, R.L.; Tamanaha, C.R.; Zhong, L.; Bounnak, S.; Whitman, L.J.;
Colton, R.J. A DNA array sensor utilizing magnetic microbeads and magnetoelectronic detection. J. Magn.
Magn. Mater. 2001, 225, 138–144. [CrossRef]
97. Llandro, J.; Palfreyman, J.J.; Ionescu, A.; Barnes, C.H.W. Magnetic biosensor technologies for medical
applications: A review. Med. Biol. Eng. Comput. 2010, 48, 977–998. [CrossRef] [PubMed]
98. Wang, S.X.; Li, G. Advances in Giant Magnetoresistance Biosensors With Magnetic Nanoparticle Tags:
Review and Outlook. IEEE Trans. Magn. 2008, 44, 1687–1702. [CrossRef]
99. Enpuku, K.; Minotani, T.; Gima, T.; Kuroki, Y.; Itoh, Y.; Yamashita, M.; Katakura, Y.; Kuhara, S. Detection of
Magnetic Nanoparticles with Superconducting Quantum Interference Device (SQUID) Magnetometer and
Application to Immunoassays. Jpn. J. Appl. Phys. 1999, 38, L1102–L1105. [CrossRef]
100. Enpuku, K.; Soejima, K.; Nishimoto, T.; Tokumitsu, H.; Kuma, H.; Hamasaki, N.; Yoshinaga, K. Liquid
phase immunoassay utilizing magnetic marker and high Tc superconducting quantum interference device.
J. Appl. Phys. 2006, 100, 54701. [CrossRef]
101. Tsai, H.Y.; Hsu, C.F.; Chiu, I.W.; Fuh, C.B. Detection of C-reactive protein based on immunoassay using
antibody-conjugated magnetic nanoparticles. Anal. Chem. 2007, 79, 8416–8419. [CrossRef] [PubMed]
102. Kriz, C.B.; Rådevik, K.; Kriz, D. Magnetic permeability measurements in bioanalysis and biosensors.
Anal. Chem. 1996, 68, 1966–1970. [CrossRef] [PubMed]
103. Ibraimi, F.; Kriz, K.; Merin, H.; Kriz, D. Magnetic permeability based diagnostic test for the determination
of the canine C-reactive protein concentration in undiluted whole blood. J. Magn. Magn. Mater. 2009, 321,
1632–1634. [CrossRef]
104. Kriz, K.; Ibraimi, F.; Lu, M.; Hansson, L.-O.; Kriz, D. Detection of C-reactive protein utilizing magnetic
permeability detection based immunoassays. Anal. Chem. 2005, 77, 5920–5924. [CrossRef] [PubMed]
105. Ibraimi, F.; Kriz, D.; Lu, M.; Hansson, L.-O.; Kriz, K. Rapid one-step whole blood C-reactive protein magnetic
permeability immunoassay with monoclonal antibody conjugated nanoparticles as superparamagnetic labels
and enhanced sedimentation. Anal. Bioanal. Chem. 2006, 384, 651–657. [CrossRef] [PubMed]
106. Ibraimi, F.; Ekberg, B.; Kriz, D.; Danielsson, G.; Bülow, L. Preparation of a portable point-of-care in vitro
diagnostic system, for quantification of canine C-reactive protein, based on a magnetic two-site immunoassay.
Anal. Bioanal. Chem. 2013, 405, 6001–6007. [CrossRef] [PubMed]
107. Kriz, K.; Gehrke, J.; Kriz, D. Advancements toward magneto immunoassays. Biosens. Bioelectron. 1998, 13,
817–823. [CrossRef]
108. Lu, M.; Ibraimi, F.; Kriz, D.; Kriz, K. A combination of magnetic permeability detection with nanometer-scaled
superparamagnetic tracer and its application for one-step detection of human urinary albumin in undiluted
urine. Biosens. Bioelectron. 2006, 21, 2248–2254. [CrossRef] [PubMed]
109. Abrahamsson, D.; Kriz, K.; Lu, M.; Kriz, D. A preliminary study on DNA detection based on relative
magnetic permeability measurements and histone H1 conjugated superparamagnetic nanoparticles as
magnetic tracers. Biosens. Bioelectron. 2004, 19, 1549–1557. [CrossRef] [PubMed]
110. Cullity, B.D.; Graham, C.D. Introduction to Magnetic Materials, 2nd ed.; IEEE/Wiley: Hoboken, NJ, USA, 2009.
111. Debye, P.J.W. Polar Molecules; The Chemical Catalog Company Inc.: New York, NY, USA, 1929.
112. Kötitz, R.; Weitschies, W.; Trahms, L.; Brewer, W.; Semmler, W. Determination of the binding reaction between
avidin and biotin by relaxation measurements of magnetic nanoparticles. J. Magn. Magn. Mater. 1999, 194,
62–68. [CrossRef]
113. Coey, J.M.D. Magnetism and Magnetic Materials; Cambridge University Press: Cambridge, UK; New York, NY,
USA, 2009.
Sensors 2016, 16, 828 40 of 49
114. Fannin, P.C.; Charles, S.W. The study of a ferrofluid exhibiting both Brownian and Neel relaxation. J. Phys. D
Appl. Phys. 1989, 22, 187–191. [CrossRef]
115. Chemla, Y.R.; Grossman, H.L.; Poon, Y.; McDermott, R.; Stevens, R.; Alper, M.D.; Clarke, J. Ultrasensitive
magnetic biosensor for homogeneous immunoassay. Proc. Natl. Acad. Sci. USA 2000, 97, 14268–14272.
[CrossRef] [PubMed]
116. Lee, S.; Myers, W.R.; Grossman, H.L.; Cho, H.-M.; Chemla, Y.R.; Clarke, J. Magnetic gradiometer based on
a high-transition temperature superconducting quantum interference device for improved sensitivity of
a biosensor. Appl. Phys. Lett. 2002, 81, 3094. [CrossRef]
117. Grossman, H.L.; Myers, W.R.; Vreeland, V.J.; Bruehl, R.; Alper, M.D.; Bertozzi, C.R.; Clarke, J. Detection of
bacteria in suspension by using a superconducting quantum interference device. Proc. Natl. Acad. Sci. USA
2004, 101, 129–134. [CrossRef] [PubMed]
118. Weitschies, W.; Kötitz, R.; Bunte, T.; Trahms, L. Determination of relaxing or remanent nanoparticle
magnetization provides a novel binding-specific technique for the evaluation of immunoassays.
Pharm. Pharmacol. Lett. 1997, 7, 5–8.
119. Matz, H.; Drung, D.; Hartwig, S.; Groß, H.; Kötitz, R.; Müller, W.; Vass, A.; Weitschies, W.; Trahms, L.
A SQUID measurement system for immunoassays. Appl. Supercond. 1998, 6, 577–583. [CrossRef]
120. Lange, J.; Kötitz, R.; Haller, A.; Trahms, L.; Semmler, W.; Weitschies, W. Magnetorelaxometry—A new
binding specific detection method based on magnetic nanoparticles. J. Magn. Magn. Mater. 2002, 252,
381–383. [CrossRef]
121. Kotitz, R.; Matz, H.; Trahms, L.; Koch, H.; Weitschies, W.; Rheinlander, T.; Semmler, W.; Bunte, T. SQUID
based remanence measurements for immunoassays. IEEE Trans. Appl. Supercond. 1997, 7, 3678–3681.
[CrossRef]
122. Eberbeck, D.; Bergemann, C.; Hartwig, S.; Steinhoff, U.; Trahms, L. Binding kinetics of magnetic nanoparticles
on latex beads and yeast cells studied by magnetorelaxometry. J. Magn. Magn. Mater. 2005, 289, 435–438.
[CrossRef]
123. Eberbeck, D.; Bergemann, C.; Wiekhorst, F.; Steinhoff, U.; Trahms, L. Quantification of specific bindings of
biomolecules by magnetorelaxometry. J. Nanobiotechnol. 2008, 6, 13. [CrossRef] [PubMed]
124. Yang, H.C.; Yang, S.Y.; Fang, G.L.; Huang, W.H.; Liu, C.H.; Liao, S.H.; Horng, H.E.; Hong, C.-Y. Magnetic
relaxation measurement in immunoassay using high-transition-temperature superconducting quantum
interference device system. J. Appl. Phys. 2006, 99, 124701. [CrossRef]
125. Enpuku, K.; Tanaka, T.; Matsuda, T.; Kuma, H.; Hamasaki, N.; Dang, F.; Enomoto, N.; Hojo, J.; Yoshinaga, K.;
Ludwig, F.; et al. Liquid Phase Immunoassay Using Magnetic Markers and Superconducting Quantum
Interference Device. Jpn. J. Appl. Phys. 2007, 46, 7524–7529. [CrossRef]
126. Enpuku, K.; Tokumitsu, H.; Sugimoto, Y.; Kuma, H.; Hamasaki, N.; Tsukamoto, A.; Mizoguchi, T.;
Kandori, A.; Yoshinaga, K.; Kanzaki, H.; et al. Fast Detection of Biological Targets With Magnetic Marker and
SQUID. IEEE Trans. Appl. Supercond. 2009, 19, 844–847. [CrossRef]
127. Uchida, S.; Higuchi, Y.; Ueoka, Y.; Yoshida, T.; Enpuku, K.; Adachi, S.; Tanabe, K.; Tsukamoto, A.; Kandori, A.
Highly Sensitive Liquid-Phase Detection of Biological Targets With Magnetic Markers and High Tc SQUID.
IEEE Trans. Appl. Supercond. 2014, 24, 1–5. [CrossRef]
128. Hofmann, A.; Wenzel, D.; Becher, U.M.; Freitag, D.F.; Klein, A.M.; Eberbeck, D.; Schulte, M.; Zimmermann, K.;
Bergemann, C.; Gleich, B.; et al. Combined targeting of lentiviral vectors and positioning of transduced cells
by magnetic nanoparticles. Proc. Natl. Acad. Sci. USA 2009, 106, 44–49. [CrossRef] [PubMed]
129. Ludwig, F.; Heim, E.; Mäuselein, S.; Eberbeck, D.; Schilling, M. Magnetorelaxometry of magnetic
nanoparticles with fluxgate magnetometers for the analysis of biological targets. J. Magn. Magn. Mater.
2005, 293, 690–695. [CrossRef]
130. Ludwig, F.; Mäuselein, S.; Heim, E.; Schilling, M. Magnetorelaxometry of magnetic nanoparticles in
magnetically unshielded environment utilizing a differential fluxgate arrangement. Rev. Sci. Instrum.
2005, 76, 106102. [CrossRef]
131. Heim, E.; Ludwig, F.; Schilling, M. Binding assays with streptavidin-functionalized superparamagnetic
nanoparticles and biotinylated analytes using fluxgate magnetorelaxometry. J. Magn. Magn. Mater. 2009, 321,
1628–1631. [CrossRef]
132. Connolly, J.; St Pierre, T.G. Proposed biosensors based on time-dependent properties of magnetic fluids.
J. Magn. Magn. Mater. 2001, 225, 156–160. [CrossRef]
Sensors 2016, 16, 828 41 of 49
133. Dieckhoff, J.H.; Yoshida, T.; Enpuku, K.; Schilling, M.; Ludwig, F. Homogeneous Bioassays Based on the
Manipulation of Magnetic Nanoparticles by Rotating and Alternating Magnetic Fields—A Comparison.
IEEE Trans. Magn. 2012, 48, 3792–3795. [CrossRef]
134. Astalan, A.P.; Ahrentorp, F.; Johansson, C.; Larsson, K.; Krozer, A. Biomolecular reactions studied using
changes in Brownian rotation dynamics of magnetic particles. Biosens. Bioelectron. 2004, 19, 945–951.
[CrossRef] [PubMed]
135. Chung, S.H.; Hoffmann, A.; Bader, S.D.; Liu, C.; Kay, B.; Makowski, L.; Chen, L. Biological sensors based on
Brownian relaxation of magnetic nanoparticles. Appl. Phys. Lett. 2004, 85, 2971. [CrossRef]
136. Chung, S.-H.; Hoffmann, A.; Guslienko, K.; Bader, S.D.; Liu, C.; Kay, B.; Makowski, L.; Chen, L. Biological
sensing with magnetic nanoparticles using Brownian relaxation (invited). J. Appl. Phys. 2005, 97, 10R101.
[CrossRef]
137. Bao, Y.; Pakhomov, A.B.; Krishnan, K.M. Brownian magnetic relaxation of water-based cobalt nanoparticle
ferrofluids. J. Appl. Phys. 2006, 99, 08H107. [CrossRef]
138. Fornara, A.; Johansson, P.; Petersson, K.; Gustafsson, S.; Qin, J.; Olsson, E.; Ilver, D.; Krozer, A.;
Muhammed, M.; Johansson, C. Tailored magnetic nanoparticles for direct and sensitive detection of
biomolecules in biological samples. Nano Lett. 2008, 8, 3423–3428. [CrossRef] [PubMed]
139. Enpuku, K.; Tamai, Y.; Mitake, T.; Matsuo, M.; Tsukamoto, A.; Mizoguchi, T.; Kandori, A. Liquid Phase
Immunoassay Using AC Susceptibility Measurement of Magnetic Markers. Appl. Phys. Express 2009, 2,
37001. [CrossRef]
140. Enpuku, K.; Tanaka, T.; Tamai, Y.; Matsuo, M. AC susceptibility of magnetic markers in suspension for liquid
phase immunoassay. J. Magn. Magn. Mater. 2009, 321, 1621–1624. [CrossRef]
141. Enpuku, K.; Tamai, Y.; Mitake, T.; Yoshida, T.; Matsuo, M. AC susceptibility measurement of magnetic
markers in suspension for liquid phase immunoassay. J. Appl. Phys. 2010, 108, 34701. [CrossRef]
142. Strömberg, M.; Göransson, J.; Gunnarsson, K.; Nilsson, M.; Svedlindh, P.; Strømme, M. Sensitive molecular
diagnostics using volume-amplified magnetic nanobeads. Nano Lett. 2008, 8, 816–821. [CrossRef] [PubMed]
143. Strömberg, M.; Gómez de la Torre, T.Z.; Göransson, J.; Gunnarsson, K.; Nilsson, M.; Svedlindh, P.;
Strømme, M. Multiplex detection of DNA sequences using the volume-amplified magnetic nanobead
detection assay. Anal. Chem. 2009, 81, 3398–3406. [CrossRef] [PubMed]
144. Gómez de la Torre, T.Z.; Mezger, A.; Herthnek, D.; Johansson, C.; Svedlindh, P.; Nilsson, M.; Strømme, M.
Detection of rolling circle amplified DNA molecules using probe-tagged magnetic nanobeads in a portable
AC susceptometer. Biosens. Bioelectron. 2011, 29, 195–199. [CrossRef] [PubMed]
145. Gómez de la Torre, T.Z.; Ke, R.; Mezger, A.; Svedlindh, P.; Strømme, M.; Nilsson, M. Sensitive detection of
spores using volume-amplified magnetic nanobeads. Small 2012, 8, 2174–2177. [CrossRef] [PubMed]
146. Strömberg, M.; Gómez de la Torre, T.Z.; Nilsson, M.; Svedlindh, P.; Strømme, M. A magnetic nanobead-based
bioassay provides sensitive detection of single- and biplex bacterial DNA using a portable AC susceptometer.
Biotechnol. J. 2014, 9, 137–145. [CrossRef] [PubMed]
147. Park, K.; Harrah, T.; Goldberg, E.B.; Guertin, R.P.; Sonkusale, S. Multiplexed sensing based on Brownian
relaxation of magnetic nanoparticles using a compact AC susceptometer. Nanotechnology 2011, 22, 85501.
[CrossRef] [PubMed]
148. Oisjöen, F.; Schneiderman, J.F.; Astalan, A.P.; Kalabukhov, A.; Johansson, C.; Winkler, D. A new approach for
bioassays based on frequency- and time-domain measurements of magnetic nanoparticles. Biosens. Bioelectron.
2010, 25, 1008–1013. [CrossRef] [PubMed]
149. Hong, C.-Y.; Wu, C.C.; Chiu, Y.C.; Yang, S.Y.; Horng, H.E.; Yang, H.C. Magnetic susceptibility reduction
method for magnetically labeled immunoassay. Appl. Phys. Lett. 2006, 88, 212512. [CrossRef]
150. Hong, C.-Y.; Chen, W.S.; Jian, Z.F.; Yang, S.Y.; Horng, H.E.; Yang, L.C.; Yang, H.C. Wash-free immunomagnetic
detection for serum through magnetic susceptibility reduction. Appl. Phys. Lett. 2007, 90, 74105. [CrossRef]
151. Chieh, J.J.; Yang, S.Y.; Jian, Z.F.; Wang, W.C.; Horng, H.E.; Yang, H.C.; Hong, C.-Y. Hyper-high-sensitivity
wash-free magnetoreduction assay on biomolecules using high-Tc superconducting quantum interference
devices. J. Appl. Phys. 2008, 103, 14703. [CrossRef]
152. Chieh, J.J.; Yang, S.-Y.; Horng, H.-E.; Yu, C.Y.; Lee, C.L.; Wu, H.L.; Hong, C.-Y.; Yang, H.-C. Immunomagnetic
reduction assay using high-Tc superconducting-quantum-interference-device-based magnetosusceptometry.
J. Appl. Phys. 2010, 107, 74903. [CrossRef]
Sensors 2016, 16, 828 42 of 49
153. Yang, C.C.; Yang, S.Y.; Chen, H.H.; Weng, W.L.; Horng, H.E.; Chieh, J.J.; Hong, C.Y.; Yang, H.C. Effect of
molecule-particle binding on the reduction in the mixed-frequency alternating current magnetic susceptibility
of magnetic bio-reagents. J. Appl. Phys. 2012, 112, 24704. [CrossRef]
154. Chang, C.-H.; Lai, Z.-X.; Lin, H.-L.; Yang, C.-C.; Chen, H.-H.; Yang, S.-Y.; Horng, H.-E.; Hong, C.-Y.;
Yang, H.-C.; Lin, H.-C. Use of immunomagnetic reduction for C-reactive protein assay in clinical samples.
Int. J. Nanomedicine 2012, 7, 4335–4340. [PubMed]
155. Chen, C.-Y.; Chang, C.-C.; Lin, C.-W. Clinical application of immunomagnetic reduction for quantitative
measurement of insulin-like growth factor binding protein-1 in the prediction of pregnant women with
preterm premature rupture of membranes. Clin. Chim. Acta 2015, 438, 337–341. [CrossRef] [PubMed]
156. Chieh, J.-J.; Huang, K.; Chuang, C.; Wei, W.; Dong, J.; Lee, Y. Immunomagnetic Reduction Assay on
Desgammacarboxy Prothrombin for Screening of Hepatocellular Carcinoma. IEEE Trans. Biomed. Eng. 2015.
[CrossRef] [PubMed]
157. Huang, K.-W.; Yang, S.-Y.; Hong, Y.-W.; Chieh, J.-J.; Yang, C.-C.; Horng, H.-E.; Wu, C.-C.; Hong, C.-Y.;
Yang, H.-C. Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic
nanoparticles. Int. J. Nanomedicine 2012, 7, 1991–1996. [PubMed]
158. Yang, C.C.; Huang, K.W.; Yang, S.Y.; Chen, H.H.; Chen, T.C.; Ho, C.S.; Chang, S.F.; Chieh, J.J.; Horng, H.E.;
Hong, C.Y.; et al. Development for High-Accuracy In Vitro Assay of Vascular Endothelial Growth Factor
Using Nanomagnetically Labeled Immunoassay. J. Nanomater. 2013, 2013, 1–7. [CrossRef]
159. Yang, S.Y.; Chieh, J.J.; Yang, C.C.; Liao, S.H.; Chen, H.H.; Horng, H.E.; Yang, H.C.; Hong, C.Y.; Chiu, M.J.;
Chen, T.F.; et al. Clinic Applications in Assaying Ultra-Low-Concentration Bio-Markers Using HTS
SQUID-Based AC Magnetosusceptometer. IEEE Trans. Appl. Supercond. 2013, 23. [CrossRef]
160. Yang, C.-C.; Yang, S.-Y.; Chieh, J.-J.; Horng, H.-E.; Hong, C.-Y.; Yang, H.-C.; Chen, K.H.; Shih, B.Y.; Chen, T.-F.;
Chiu, M.-J. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s
disease in vitro. ACS Chem. Neurosci. 2011, 2, 500–505. [CrossRef] [PubMed]
161. Chiu, M.J.; Horng, H.E.; Chieh, J.J.; Liao, S.H.; Chen, C.H.; Shih, B.Y.; Yang, C.C.; Lee, C.L.; Chen, T.F.;
Yang, S.Y.; et al. Multi-Channel SQUID-Based Ultra-High-Sensitivity In-Vitro Detections for Bio-Markers
of Alzheimer’s Disease Via Immunomagnetic Reduction. IEEE Trans. Appl. Supercond. 2011, 21, 477–480.
[CrossRef]
162. Chiu, M.-J.; Yang, S.-Y.; Horng, H.-E.; Yang, C.-C.; Chen, T.-F.; Chieh, J.-J.; Chen, H.-H.; Chen, T.-C.; Ho, C.-S.;
Chang, S.-F.; et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s
disease. ACS Chem. Neurosci. 2013, 4, 1530–1536. [CrossRef] [PubMed]
163. Tzen, K.-Y.; Yang, S.-Y.; Chen, T.-F.; Cheng, T.-W.; Horng, H.-E.; Wen, H.-P.; Huang, Y.-Y.; Shiue, C.-Y.;
Chiu, M.-J. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer’s disease.
ACS Chem. Neurosci. 2014, 5, 830–836. [CrossRef] [PubMed]
164. Chiu, M.-J.; Chen, Y.-F.; Chen, T.-F.; Yang, S.-Y.; Yang, F.-P.G.; Tseng, T.-W.; Chieh, J.-J.; Chen, J.-C.R.;
Tzen, K.-Y.; Hua, M.-S.; et al. Plasma tau as a window to the brain-negative associations with brain volume
and memory function in mild cognitive impairment and early Alzheimer’s disease. Hum. Brain Mapp.
2014, 35, 3132–3142. [CrossRef] [PubMed]
165. Chen, C.-Y.; Hwu, Y.-M.; Chen, C.-P.; Chang, C.-C. Quantitative analysis of total β-subunit of human
chorionic gonadotropin concentration in urine by immunomagnetic reduction to assist in the diagnosis of
ectopic pregnancy. Int. J. Nanomedicine 2015, 10, 2475–2483. [CrossRef] [PubMed]
166. Yang, S.Y.; Chieh, J.J.; Wang, W.C.; Yu, C.Y.; Hing, N.S.; Horng, H.E.; Hong, C.-Y.; Yang, H.C.; Chang, C.F.;
Lin, H.Y. Magnetic nanoparticles for high-sensitivity detection on nucleic acids via superconducting-
quantum-interference-device-based immunomagnetic reduction assay. J. Magn. Magn. Mater. 2011, 323,
681–685. [CrossRef]
167. Yang, S.Y.; Jian, Z.F.; Chieh, J.J.; Horng, H.E.; Yang, H.C.; Huang, I.J.; Hong, C.-Y. Wash-free, antibody-assisted
magnetoreduction assays of orchid viruses. J. Virol. Methods 2008, 149, 334–337. [CrossRef] [PubMed]
168. Yang, S.Y.; Chieh, J.J.; Wang, W.C.; Yu, C.Y.; Lan, C.B.; Chen, J.H.; Horng, H.E.; Hong, C.-Y.; Yang, H.C.;
Huang, W. Ultra-highly sensitive and wash-free bio-detection of H5N1 virus by immunomagnetic reduction
assays. J. Virol. Methods 2008, 153, 250–252. [CrossRef] [PubMed]
169. Yang, S.Y.; Wang, W.C.; Lan, C.B.; Chen, C.H.; Chieh, J.J.; Horng, H.E.; Hong, C.-Y.; Yang, H.C.; Tsai, C.P.;
Yang, C.Y.; et al. Magnetically enhanced high-specificity virus detection using bio-activated magnetic
nanoparticles with antibodies as labeling markers. J. Virol. Methods 2010, 164, 14–18. [CrossRef] [PubMed]
Sensors 2016, 16, 828 43 of 49
170. Liu, B.-H.; Lin, Y.-C.; Ho, C.-S.; Yang, C.-C.; Chang, Y.-T.; Chang, J.-F.; Li, C.-Y.; Cheng, C.-S.;
Huang, J.-Y.; Lee, Y.-F.; et al. A Novel Detection Platform for Shrimp White Spot Syndrome Virus Using
an ICP11-Dependent Immunomagnetic Reduction (IMR) Assay. PLoS ONE 2015, 10, e0138207. [CrossRef]
[PubMed]
171. Yang, S.Y.; Ho, C.S.; Lee, C.L.; Shih, B.Y.; Horng, H.E.; Hong, C.-Y.; Yang, H.C.; Chung, Y.H.; Chen, J.C.;
Lin, T.C. Immunomagnetic reduction assay on chloramphenicol extracted from shrimp. Food Chem. 2012, 131,
1021–1025. [CrossRef]
172. Lu, M.W.; Yang, S.Y.; Horng, H.E.; Yang, C.C.; Chieh, J.J.; Hong, Y.W.; Hong, C.Y.; Yang, H.C.; Wu, J.L.
Immunomagnetic reduction assay for nervous necrosis virus extracted from groupers. J. Virol. Methods
2012, 181, 68–72. [CrossRef] [PubMed]
173. Yang, S.Y.; Wu, J.L.; Tso, C.H.; Ngou, F.H.; Chou, H.Y.; Nan, F.H.; Horng, H.E.; Lu, M.W. A novel quantitative
immunomagnetic reduction assay for Nervous necrosis virus. J. Vet. Diagn. Invest. 2012, 24, 911–917.
[CrossRef] [PubMed]
174. Liao, S.H.; Yang, H.C.; Horng, H.E.; Chieh, J.J.; Chen, K.L.; Chen, H.H.; Chen, J.Y.; Liu, C.I.; Liu, C.W.;
Wang, L.M. Time-dependent phase lag of biofunctionalized magnetic nanoparticles conjugated with
biotargets studied with alternating current magnetic susceptometor for liquid phase immunoassays.
Appl. Phys. Lett. 2013, 103, 243703. [CrossRef]
175. Liao, S.-H.; Chen, J.-H.; Su, Y.-K.; Chen, K.-L.; Horng, H.-E.; Yang, H.-C. Assaying Biomarkers via Real-Time
Measurements of the Effective Relaxation Time of Biofunctionalized Magnetic Nanoparticles Associated
with Biotargets. J. Nanomater. 2015, 2015, 1–7. [CrossRef]
176. Tu, L.; Jing, Y.; Li, Y.; Wang, J.-P. Real-time measurement of Brownian relaxation of magnetic nanoparticles
by a mixing-frequency method. Appl. Phys. Lett. 2011, 98, 213702. [CrossRef]
177. Dieckhoff, J.; Schilling, M.; Ludwig, F. Fluxgate based detection of magnetic nanoparticle dynamics in
a rotating magnetic field. Appl. Phys. Lett. 2011, 99, 112501. [CrossRef]
178. Dieckhoff, J.; Lak, A.; Schilling, M.; Ludwig, F. Protein detection with magnetic nanoparticles in a rotating
magnetic field. J. Appl. Phys. 2014, 115, 24701. [CrossRef]
179. Dieckhoff, J.; Schrittwieser, S.; Schotter, J.; Remmer, H.; Schilling, M.; Ludwig, F. Single-core magnetic
markers in rotating magnetic field based homogeneous bioassays and the law of mass action. J. Magn.
Magn. Mater. 2015, 380, 205–208. [CrossRef]
180. Demas, V.; Lowery, T.J. Magnetic resonance for in vitro medical diagnostics: Superparamagnetic
nanoparticle-based magnetic relaxation switches. New J. Phys. 2011, 13, 25005. [CrossRef]
181. Haun, J.B.; Yoon, T.-J.; Lee, H.; Weissleder, R. Magnetic nanoparticle biosensors. Wiley Interdiscip.
Rev. Nanomed. Nanobiotechnol. 2010, 2, 291–304. [CrossRef] [PubMed]
182. Koh, I.; Josephson, L. Magnetic nanoparticle sensors. Sensors 2009, 9, 8130–8145. [CrossRef] [PubMed]
183. Lee, H.; Shin, T.-H.; Cheon, J.; Weissleder, R. Recent Developments in Magnetic Diagnostic Systems.
Chem. Rev. 2015, 115, 10690–10724. [CrossRef] [PubMed]
184. Shao, H.; Min, C.; Issadore, D.; Liong, M.; Yoon, T.-J.; Weissleder, R.; Lee, H. Magnetic Nanoparticles and
microNMR for Diagnostic Applications. Theranostics 2012, 2, 55–65. [CrossRef] [PubMed]
185. Issadore, D.; Park, Y.I.; Shao, H.; Min, C.; Lee, K.; Liong, M.; Weissleder, R.; Lee, H. Magnetic sensing
technology for molecular analyses. Lab Chip 2014, 14, 2385–2397. [CrossRef] [PubMed]
186. Ahmadov, T.O.; Joshi, P.; Zhang, J.; Nahan, K.; Caruso, J.A.; Zhang, P. Paramagnetic relaxation based
biosensor for selective dopamine detection. Chem. Commun. 2015, 51, 11425–11428. [CrossRef] [PubMed]
187. Jacques, V.; Dumas, S.; Sun, W.-C.; Troughton, J.S.; Greenfield, M.T.; Caravan, P. High-relaxivity magnetic
resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity.
Investig. Radiol. 2010, 45, 613–624. [CrossRef] [PubMed]
188. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R.N. Magnetic iron oxide
nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological
applications. Chem. Rev. 2008, 108, 2064–2110. [CrossRef] [PubMed]
189. Abbasi, A.Z.; Gutiérrez, L.; del Mercato, L.L.; Herranz, F.; Chubykalo-Fesenko, O.; Veintemillas-Verdaguer, S.;
Parak, W.J.; Morales, M.P.; González, J.M.; Hernando, A.; et al. Magnetic Capsules for NMR Imaging: Effect
of Magnetic Nanoparticles Spatial Distribution and Aggregation. J. Phys. Chem. C 2011, 115, 6257–6264.
[CrossRef]
Sensors 2016, 16, 828 44 of 49
190. Min, C.; Shao, H.; Liong, M.; Yoon, T.-J.; Weissleder, R.; Lee, H. Mechanism of magnetic relaxation switching
sensing. ACS Nano 2012, 6, 6821–6828. [CrossRef] [PubMed]
191. Lee, H.; Sun, E.; Ham, D.; Weissleder, R. Chip-NMR biosensor for detection and molecular analysis of cells.
Nat. Med. 2008, 14, 869–874. [CrossRef] [PubMed]
192. Brooks, R.A. T(2)-shortening by strongly magnetized spheres: A chemical exchange model.
Magn. Reson. Med. 2002, 47, 388–391. [CrossRef] [PubMed]
193. Gillis, P.; Moiny, F.; Brooks, R.A. On T(2)-shortening by strongly magnetized spheres: A partial refocusing
model. Magn. Reson. Med. 2002, 47, 257–263. [CrossRef] [PubMed]
194. Brooks, R.A.; Moiny, F.; Gillis, P. On T2-shortening by weakly magnetized particles: the chemical exchange
model. Magn. Reson. Med. 2001, 45, 1014–1020. [CrossRef] [PubMed]
195. Josephson, L.; Perez, J.M.; Weissleder, R. Magnetic Nanosensors for the Detection of Oligonucleotide
Sequences. Angew. Chem. Int. Ed. 2001, 40, 3204–3206. [CrossRef]
196. Perez, J.M.; O’Loughin, T.; Simeone, F.J.; Weissleder, R.; Josephson, L. DNA-Based Magnetic Nanoparticle
Assembly Acts as a Magnetic Relaxation Nanoswitch Allowing Screening of DNA-Cleaving Agents. J. Am.
Chem. Soc. 2002, 124, 2856–2857. [CrossRef] [PubMed]
197. Perez, J.M.; Josephson, L.; O’Loughlin, T.; Högemann, D.; Weissleder, R. Magnetic relaxation switches
capable of sensing molecular interactions. Nat. Biotechnol. 2002, 20, 816–820. [CrossRef] [PubMed]
198. Alcantara, D.; Guo, Y.; Yuan, H.; Goergen, C.J.; Chen, H.H.; Cho, H.; Sosnovik, D.E.; Josephson, L.
Fluorochrome-functionalized magnetic nanoparticles for high-sensitivity monitoring of the polymerase
chain reaction by magnetic resonance. Angew. Chem. Int. Ed. 2012, 51, 6904–6907. [CrossRef] [PubMed]
199. Liong, M.; Hoang, A.N.; Chung, J.; Gural, N.; Ford, C.B.; Min, C.; Shah, R.R.; Ahmad, R.;
Fernandez-Suarez, M.; Fortune, S.M.; et al. Magnetic barcode assay for genetic detection of pathogens.
Nat. Commun. 2013, 4, 1752. [CrossRef] [PubMed]
200. Chung, H.J.; Castro, C.M.; Im, H.; Lee, H.; Weissleder, R. A magneto-DNA nanoparticle system for rapid
detection and phenotyping of bacteria. Nat. Nanotechnol. 2013, 8, 369–375. [CrossRef] [PubMed]
201. Zhao, M.; Josephson, L.; Tang, Y.; Weissleder, R. Magnetic Sensors for Protease Assays. Angew. Chem. Int. Ed.
2003, 42, 1375–1378. [CrossRef] [PubMed]
202. Bamrungsap, S.; Shukoor, M.I.; Chen, T.; Sefah, K.; Tan, W. Detection of lysozyme magnetic relaxation
switches based on aptamer-functionalized superparamagnetic nanoparticles. Anal. Chem. 2011, 83, 7795–7799.
[CrossRef] [PubMed]
203. Grimm, J.; Perez, J.M.; Josephson, L.; Weissleder, R. Novel nanosensors for rapid analysis of telomerase
activity. Cancer Res. 2004, 64, 639–643. [CrossRef] [PubMed]
204. Santiesteban, O.J.; Kaittanis, C.; Perez, J.M. Assessment of molecular interactions through magnetic relaxation.
Angew. Chem. Int. Ed. 2012, 51, 6728–6732. [CrossRef] [PubMed]
205. Perez, J.M.; Simeone, F.J.; Saeki, Y.; Josephson, L.; Weissleder, R. Viral-induced self-assembly of magnetic
nanoparticles allows the detection of viral particles in biological media. J. Am. Chem. Soc. 2003, 125,
10192–10193. [CrossRef] [PubMed]
206. Chen, Y.; Xianyu, Y.; Wang, Y.; Zhang, X.; Cha, R.; Sun, J.; Jiang, X. One-step detection of pathogens and
viruses: combining magnetic relaxation switching and magnetic separation. ACS Nano 2015, 9, 3184–3191.
[CrossRef] [PubMed]
207. Bamrungsap, S.; Chen, T.; Shukoor, M.I.; Chen, Z.; Sefah, K.; Chen, Y.; Tan, W. Pattern recognition of cancer
cells using aptamer-conjugated magnetic nanoparticles. ACS Nano 2012, 6, 3974–3981. [CrossRef] [PubMed]
208. Xu, Z.; Kuang, H.; Yan, W.; Hao, C.; Xing, C.; Wu, X.; Wang, L.; Xu, C. Facile and rapid magnetic relaxation
switch immunosensor for endocrine-disrupting chemicals. Biosens. Bioelectron. 2012, 32, 183–187. [CrossRef]
[PubMed]
209. Tsourkas, A.; Hofstetter, O.; Hofstetter, H.; Weissleder, R.; Josephson, L. Magnetic relaxation switch
immunosensors detect enantiomeric impurities. Angew. Chem. Int. Ed. 2004, 43, 2395–2399. [CrossRef]
[PubMed]
210. Chen, Y.; Xie, M. A magnetic relaxation switching immunosensor for one-step detection of salbutamol based
on gold nanoparticle–streptavidin conjugate. RSC Adv. 2015, 5, 95401–95404. [CrossRef]
211. Santiesteban, O.J.; Kaittanis, C.; Perez, J.M. Identification of toxin inhibitors using a magnetic
nanosensor-based assay. Small 2014, 10, 1202–1211. [CrossRef] [PubMed]
Sensors 2016, 16, 828 45 of 49
212. Atanasijevic, T.; Shusteff, M.; Fam, P.; Jasanoff, A. Calcium-sensitive MRI contrast agents based on
superparamagnetic iron oxide nanoparticles and calmodulin. Proc. Natl. Acad. Sci. USA 2006, 103,
14707–14712. [CrossRef] [PubMed]
213. Sun, N.; Yoon, T.-J.; Lee, H.; Andress, W.; Weissleder, R.; Ham, D. Palm NMR and 1-Chip NMR. IEEE J. Solid
State Circuits 2011, 46, 342–352. [CrossRef]
214. Issadore, D.; Min, C.; Liong, M.; Chung, J.; Weissleder, R.; Lee, H. Miniature magnetic resonance system for
point-of-care diagnostics. Lab Chip 2011, 11, 2282–2287. [CrossRef] [PubMed]
215. Daniel, K.D.; Kim, G.Y.; Vassiliou, C.C.; Galindo, M.; Guimaraes, A.R.; Weissleder, R.; Charest, A.; Langer, R.;
Cima, M.J. Implantable diagnostic device for cancer monitoring. Biosens. Bioelectron. 2009, 24, 3252–3257.
[CrossRef] [PubMed]
216. Daniel, K.D.; Kim, G.Y.; Vassiliou, C.C.; Jalali-Yazdi, F.; Langer, R.; Cima, M.J. Multi-reservoir device for
detecting a soluble cancer biomarker. Lab Chip 2007, 7, 1288–1293. [CrossRef] [PubMed]
217. Ling, Y.; Pong, T.; Vassiliou, C.C.; Huang, P.L.; Cima, M.J. Implantable magnetic relaxation sensors measure
cumulative exposure to cardiac biomarkers. Nat. Biotechnol. 2011, 29, 273–277. [CrossRef] [PubMed]
218. Anker, J.N.; Kopelman, R. Magnetically modulated optical nanoprobes. Appl. Phys. Lett. 2003, 82, 1102.
[CrossRef]
219. Anker, J.N.; Behrend, C.; Kopelman, R. Aspherical magnetically modulated optical nanoprobes
(MagMOONs). J. Appl. Phys. 2003, 93, 6698. [CrossRef]
220. Petkus, M.M.; McLauchlin, M.; Vuppu, A.K.; Rios, L.; Garcia, A.A.; Hayes, M.A. Detection of FITC-cortisol
via modulated supraparticle lighthouses. Anal. Chem. 2006, 78, 1405–1411. [CrossRef] [PubMed]
221. Hayes, M.A.; Petkus, M.M.; Garcia, A.A.; Taylor, T.; Mahanti, P. Demonstration of sandwich and competitive
modulated supraparticle fluoroimmunoassay applied to cardiac protein biomarker myoglobin. Analyst
2009, 134, 533–541. [CrossRef] [PubMed]
222. Mahanti, P.; Taylor, T.; Hayes, M.A.; Cochran, D.; Petkus, M.M. Improved detectability and signal strength for
rotating phase fluorescence immunoassays through image processing. Analyst 2011, 136, 365–373. [CrossRef]
[PubMed]
223. Woolley, C.F.; Hayes, M.A. Sensitive Detection of Cardiac Biomarkers Using a Magnetic Microbead
Immunoassay. Anal. Methods 2015, 7, 8632–8639. [CrossRef] [PubMed]
224. Yang, J.; Donolato, M.; Pinto, A.; Bosco, F.G.; Hwu, E.-T.; Chen, C.-H.; Alstrøm, T.S.; Lee, G.-H.;
Schäfer, T.; Vavassori, P.; et al. Blu-ray based optomagnetic aptasensor for detection of small molecules.
Biosens. Bioelectron. 2016, 75, 396–403. [CrossRef] [PubMed]
225. Baudry, J.; Rouzeau, C.; Goubault, C.; Robic, C.; Cohen-Tannoudji, L.; Koenig, A.; Bertrand, E.; Bibette, J.
Acceleration of the recognition rate between grafted ligands and receptors with magnetic forces. Proc. Natl.
Acad. Sci. USA 2006, 103, 16076–16078. [CrossRef] [PubMed]
226. Singer, J.M.; Plotz, C.M. The latex fixation test. Am. J. Med. 1956, 21, 888–892. [CrossRef]
227. Lee, N.-K.; Johner, A.; Thalmann, F.; Cohen-Tannoudji, L.; Bertrand, E.; Baudry, J.; Bibette, J.; Marques, C.M.
Ligand-receptor interactions in chains of colloids: When reactions are limited by rotational diffusion.
Langmuir 2008, 24, 1296–1307. [CrossRef] [PubMed]
228. Cohen-Tannoudji, L.; Bertrand, E.; Baudry, J.; Robic, C.; Goubault, C.; Pellissier, M.; Johner, A.; Thalmann, F.;
Lee, N.K.; Marques, C.M.; et al. Measuring the kinetics of biomolecular recognition with magnetic colloids.
Phys. Rev. Lett. 2008, 100, 108301. [CrossRef] [PubMed]
229. Daynès, A.; Temurok, N.; Gineys, J.-P.; Cauet, G.; Nerin, P.; Baudry, J.; Bibette, J. Fast Magnetic Field-Enhanced
Linear Colloidal Agglutination Immunoassay. Anal. Chem. 2015, 87, 7583–7587. [CrossRef] [PubMed]
230. Ramiandrisoa, D.; Brient-Litzler, E.; Daynes, A.; Compain, E.; Bibette, J.; Baudry, J. Optical protein detection
based on magnetic clusters rotation. N. Biotechnol. 2015, 32, 467–472. [CrossRef] [PubMed]
231. Park, S.Y.; Handa, H.; Sandhu, A. Magneto-optical biosensing platform based on light scattering from
self-assembled chains of functionalized rotating magnetic beads. Nano Lett. 2010, 10, 446–451. [CrossRef]
[PubMed]
232. Ranzoni, A.; Schleipen, J.; van Ijzendoorn, L.J.; Prins, M.W.J. Frequency-selective rotation of two-particle
nanoactuators for rapid and sensitive detection of biomolecules. Nano Lett. 2011, 11, 2017–2022. [CrossRef]
[PubMed]
Sensors 2016, 16, 828 46 of 49
233. Ranzoni, A.; Janssen, X.J.A.; Ovsyanko, M.; van Ijzendoorn, L.J.; Prins, M.W.J. Magnetically controlled
rotation and torque of uniaxial microactuators for lab-on-a-chip applications. Lab Chip 2010, 10, 179–188.
[CrossRef] [PubMed]
234. Ranzoni, A.; Sabatte, G.; van Ijzendoorn, L.J.; Prins, M.W.J. One-step homogeneous magnetic nanoparticle
immunoassay for biomarker detection directly in blood plasma. ACS Nano 2012, 6, 3134–3141. [CrossRef]
[PubMed]
235. Kinnunen, P.; McNaughton, B.H.; Albertson, T.; Sinn, I.; Mofakham, S.; Elbez, R.; Newton, D.W.; Hunt, A.;
Kopelman, R. Self-assembled magnetic bead biosensor for measuring bacterial growth and antimicrobial
susceptibility testing. Small 2012, 8, 2477–2482. [CrossRef] [PubMed]
236. McNaughton, B.H.; Kehbein, K.A.; Anker, J.N.; Kopelman, R. Sudden breakdown in linear response of
a rotationally driven magnetic microparticle and application to physical and chemical microsensing. J. Phys.
Chem. B 2006, 110, 18958–18964. [CrossRef] [PubMed]
237. Hecht, A.; Commiskey, P.; Shah, N.; Kopelman, R. Bead assembly magnetorotation as a signal transduction
method for protein detection. Biosens. Bioelectron. 2013, 48, 26–32. [CrossRef] [PubMed]
238. Kinnunen, P.; Carey, M.E.; Craig, E.; Brahmasandra, S.N.; McNaughton, B.H. Rapid bacterial growth and
antimicrobial response using self-assembled magnetic bead sensors. Sens. Actuator B Chem. 2014, 190,
265–269. [CrossRef]
239. Donolato, M.; Antunes, P.; Gómez de la Torre, T.Z.; Hwu, E.-T.; Chen, C.-H.; Burger, R.; Rizzi, G.; Bosco, F.G.;
Strømme, M.; Boisen, A.; et al. Quantification of rolling circle amplified DNA using magnetic nanobeads and
a Blu-ray optical pick-up unit. Biosens. Bioelectron. 2015, 67, 649–655. [CrossRef] [PubMed]
240. Antunes, P.; Watterson, D.; Parmvi, M.; Burger, R.; Boisen, A.; Young, P.; Cooper, M.A.; Hansen, M.F.;
Ranzoni, A.; Donolato, M. Quantification of NS1 dengue biomarker in serum via optomagnetic nanocluster
detection. Sci. Rep. 2015, 5, 16145. [CrossRef] [PubMed]
241. Donolato, M.; Antunes, P.; Bejhed, R.S.; Gómez de la Torre, T.Z.; Østerberg, F.W.; Strömberg, M.; Nilsson, M.;
Strømme, M.; Svedlindh, P.; Hansen, M.F.; et al. Novel readout method for molecular diagnostic assays based
on optical measurements of magnetic nanobead dynamics. Anal. Chem. 2015, 87, 1622–1629. [CrossRef]
[PubMed]
242. Mezger, A.; Fock, J.; Antunes, P.; Østerberg, F.W.; Boisen, A.; Nilsson, M.; Hansen, M.F.; Ahlford, A.;
Donolato, M. Scalable DNA-Based Magnetic Nanoparticle Agglutination Assay for Bacterial Detection in
Patient Samples. ACS Nano 2015, 9, 7374–7382. [CrossRef] [PubMed]
243. Tian, B.; Bejhed, R.S.; Svedlindh, P.; Strömberg, M. Blu-ray optomagnetic measurement based competitive
immunoassay for Salmonella detection. Biosens. Bioelectron. 2016, 77, 32–39. [CrossRef] [PubMed]
244. Muller, D.A.; Young, P.R. The flavivirus NS1 protein: Molecular and structural biology, immunology, role
in pathogenesis and application as a diagnostic biomarker. Antiviral Res. 2013, 98, 192–208. [CrossRef]
[PubMed]
245. Leslie, D.C.; Li, J.; Strachan, B.C.; Begley, M.R.; Finkler, D.; Bazydlo, L.A.L.; Barker, N.S.; Haverstick, D.M.;
Utz, M.; Landers, J.P. New detection modality for label-free quantification of DNA in biological samples via
superparamagnetic bead aggregation. J. Am. Chem. Soc. 2012, 134, 5689–5696. [CrossRef] [PubMed]
246. Strachan, B.C.; Sloane, H.S.; Lee, J.C.; Leslie, D.C.; Landers, J.P. Investigation of the DNA target design
parameters for effective hybridization-induced aggregation of particles for the sequence-specific detection of
DNA. Analyst 2015, 140, 2008–2015. [CrossRef] [PubMed]
247. Nelson, D.A.; Strachan, B.C.; Sloane, H.S.; Li, J.; Landers, J.P. Dual-force aggregation of magnetic particles
enhances label-free quantification of DNA at the sub-single cell level. Anal. Chim Acta 2014, 819, 34–41.
[CrossRef] [PubMed]
248. Melzak, K.A.; Sherwood, C.S.; Turner, R.F.; Haynes, C.A. Driving Forces for DNA Adsorption to Silica in
Perchlorate Solutions. J. Colloid Interface Sci. 1996, 181, 635–644. [CrossRef]
249. Li, J.; Liu, Q.; Xiao, L.; Haverstick, D.M.; Dewald, A.; Columbus, L.; Kelly, K.; Landers, J.P. Label-free method
for cell counting in crude biological samples via paramagnetic bead aggregation. Anal. Chem. 2013, 85,
11233–11239. [CrossRef] [PubMed]
250. Sloane, H.S.; Kelly, K.A.; Landers, J.P. Rapid KRAS Mutation Detection via Hybridization-Induced
Aggregation of Microbeads. Anal. Chem. 2015, 87, 10275–10282. [CrossRef] [PubMed]
Sensors 2016, 16, 828 47 of 49
251. DuVall, J.A.; Borba, J.C.; Shafagati, N.; Luzader, D.; Shukla, N.; Li, J.; Kehn-Hall, K.; Kendall, M.M.;
Feldman, S.H.; Landers, J.P. Optical Imaging of Paramagnetic Bead-DNA Aggregation Inhibition Allows for
Low Copy Number Detection of Infectious Pathogens. PLoS ONE 2015, 10, e0129830. [CrossRef] [PubMed]
252. Li, J.; Liu, Q.; Alsamarri, H.; Lounsbury, J.A.; Haversitick, D.M.; Landers, J.P. Label-free DNA quantification
via a ‘pipette, aggregate and blot’ (PAB) approach with magnetic silica particles on filter paper. Lab Chip
2013, 13, 955–961. [CrossRef] [PubMed]
253. Lin, C.; Zhang, Y.; Zhou, X.; Yao, B.; Fang, Q. Naked-eye detection of nucleic acids through rolling circle
amplification and magnetic particle mediated aggregation. Biosens. Bioelectron. 2013, 47, 515–519. [CrossRef]
[PubMed]
254. Chen, Y.; Xianyu, Y.; Sun, J.; Niu, Y.; Wang, Y.; Jiang, X. One-step detection of pathogens and cancer
biomarkers by the naked eye based on aggregation of immunomagnetic beads. Nanoscale 2015, 8, 1100–1107.
[CrossRef] [PubMed]
255. Bentivegna, F.; Nyvlt, M.; Ferré, J.; Jamet, J.P.; Brun, A.; Višňovsky, S.; Urban, R. Magnetically textured
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